<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00318461</url>
  </required_header>
  <id_info>
    <org_study_id>NN2211-1572</org_study_id>
    <nct_id>NCT00318461</nct_id>
  </id_info>
  <brief_title>To Compare the Effect of Liraglutide When Given Together With Metformin With the Effect of Metformin Given Alone and With the Effect of Glimepiride and Metformin Given Together</brief_title>
  <acronym>LEAD-2</acronym>
  <official_title>Liraglutide Effect and Action in Diabetes (LEAD-2): Effect on Glycaemic Control After Once Daily Administration of Liraglutide in Combination With Metformin Versus Metformin Monotherapy Versus Metformin and Glimepiride Combination Therapy in Subjects With Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is conducted in Europe, Oceania, Africa, Asia and South America. This trial is
      designed to show the effect of treatment with liraglutide when adding to existing metformin
      therapy and to compare it with the effects of metformin monotherapy and combination therapy
      of metformin and glimepiride. Two trial periods: A 6 month (26 weeks) randomised,
      double-blinded period followed by an 18 months open-label extension, in total 2 years (104
      weeks).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2006</start_date>
  <completion_date type="Actual">November 2008</completion_date>
  <primary_completion_date type="Actual">May 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Glycosylated A1c (HbA1c) at Week 26</measure>
    <time_frame>week 0, week 26</time_frame>
    <description>Percentage point change in Glycosylated A1c (HbA1c) from baseline (week 0) to 26 weeks (end of randomisation)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Glycosylated A1c (HbA1c) at Week 104</measure>
    <time_frame>week 0, week 104</time_frame>
    <description>Change in glycosylated A1c (HbA1c) baseline (week 0) to 104 weeks (end of randomisation)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Body Weight at Week 26</measure>
    <time_frame>week 0, week 26</time_frame>
    <description>Change in body weight from baseline (week 0) to 26 weeks (end of randomisation)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Body Weight at Week 104</measure>
    <time_frame>week 0, week 104</time_frame>
    <description>Change in body weight from baseline (week 0) to 104 weeks (end of treatment)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Fasting Plasma Glucose (FPG) at Week 26</measure>
    <time_frame>week 0, week 26</time_frame>
    <description>Change in fasting plasma glucose (FPG) from baseline (week 0) to 26 weeks (end of randomisation)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Fasting Plasma Glucose (FPG) at Week 104</measure>
    <time_frame>week 0, week 104</time_frame>
    <description>Change in Fasting plasma glucose (FPG) from baseline (week 0) to 104 weeks (end of treatment)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Mean Prandial Increments of Plasma Glucose Based on Self-measured 7-point Plasma Glucose Profiles at Week 26</measure>
    <time_frame>week 0, week 26</time_frame>
    <description>Change in mean prandial increments of plasma glucose based on self-measured 7-point plasma glucose profiles from baseline (week 0) to 26 weeks (end of randomisation). The 7 time points for self-measurements were: before each meal (breakfast, lunch and dinner), at 90 min after start of each meal (breakfast, lunch and dinner) and at bedtime.
Mean prandial increments of plasma glucose were calculated as the sum of the plasma glucose differences between values measured before and after a meal (breakfast, lunch and dinner) divided by three.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Mean Prandial Increments of Plasma Glucose Based on Self-measured 7-point Plasma Glucose Profiles at Week 104</measure>
    <time_frame>week 0, week 104</time_frame>
    <description>Change in mean prandial increments of plasma glucose based on self-measured 7-point plasma glucose profiles from baseline (week 0) to 104 weeks (end of treatment). The 7 time points for self-measurements were: before each meal (breakfast, lunch and dinner), at 90 min after start of each meal (breakfast, lunch and dinner) and at bedtime.
Mean prandial increments of plasma glucose were calculated as the sum of the plasma glucose differences between values measured before and after a meal (breakfast, lunch and dinner) divided by three.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Mean Post Prandial Plasma Glucose Based on Self-measured 7-point Plasma Glucose Profiles at Week 26</measure>
    <time_frame>week 0, week 26</time_frame>
    <description>Change in mean post prandial plasma glucose from baseline (Week 0) to 26 weeks (end of randomisation). The 7 time points for self-measurements were: before each meal (breakfast, lunch and dinner), at 90 min after start of each meal (breakfast, lunch and dinner) and at bedtime. Mean post prandial plasma glucose were calculated as the sum of the post pradial plasma glucose values divided by three.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Mean Post Prandial Plasma Glucose Based on Self-measured 7-point Plasma Glucose Profiles at Week 104</measure>
    <time_frame>week 0, week 104</time_frame>
    <description>Change in mean post prandial plasma glucose from baseline (Week 0) to 104 weeks (end of treatment) The 7 time points for self-measurements were: before each meal (breakfast, lunch and dinner), at 90 min after start of each meal (breakfast, lunch and dinner) and at bedtime. Mean post prandial plasma glucose were calculated as the sum of the post pradial plasma glucose values divided by three.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Beta-cell Function at Week 26</measure>
    <time_frame>week 0, week 26</time_frame>
    <description>Change in beta cell function from baseline (week 0) to 16 weeks (end of treatment). Beta-cell function was derived from fasting plasma glucose (FPG) and fasting insulin concentrations using the homeostasic model assessment (HOMA) method which uses the assumption that normal-weight normal subjects aged under 35 years have a 100% beta-cell function (HOMA-B).
Beta-cell function: HOMA-B (%) = 20∙fasting insulin[uU/mL] divided by (FPG mmol/L]-3.5).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Beta-cell Function at Week 104</measure>
    <time_frame>week 0, week 104</time_frame>
    <description>Change in beta cell function from baseline (week 0) to 16 weeks (end of treatment). Beta-cell function was derived from fasting plasma glucose (FPG) and fasting insulin concentrations using the homeostasic model assessment (HOMA) method which uses the assumption that normal-weight normal subjects aged under 35 years have a 100% beta-cell function (HOMA-B).
Beta-cell function: HOMA-B (%) = 20∙fasting insulin[uU/mL] divided by (FPG mmol/L]-3.5).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypoglycaemic Episodes at Week 26</measure>
    <time_frame>weeks 0-26</time_frame>
    <description>Total number of hypoglycaemic episodes occuring after baseline (week 0) until week 26 (end of randomisation). Hypoglycaemic episodes were defined as major, minor, or symptoms only. Major if the subject was unable to treat her/himself. Minor if subject was able to treat her/himself and plasma glucose was below 3.1 mmol/L. Symptoms only if subject was able to treat her/himself and with no plasma glucose measurement or plasma glucose higher than or equal to 3.1 mmol/L.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypoglycaemic Episodes at Week 104</measure>
    <time_frame>weeks 0-104</time_frame>
    <description>Total number of hypoglycaemic episodes occuring after baseline (week 0) until 104 weeks (end of treatment). Hypoglycaemic episodes were defined as major, minor, or symptoms only. Major if the subject was unable to treat her/himself. Minor if subject was able to treat her/himself and plasma glucose was below 3.1 mmol/L. Symptoms only if subject was able to treat her/himself and with no plasma glucose measurement or plasma glucose higher than or equal to 3.1 mmol/L.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">1091</enrollment>
  <condition>Diabetes</condition>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Lira 0.6 + Met</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Liraglutide 0.6 mg/day + glimepiride placebo + metformin 1.5-2.0 g/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lira 1.2 + Met</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Liraglutide 1.2 mg/day + glimepiride placebo + metformin 1.5-2.0 g/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lira 1.8 + Met</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Liraglutide 1.8 mg/day + glimepiride placebo + metformin 1.5-2.0 g/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Met Mono</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Metformin 1.5-2.0 g/day + liraglutide placebo + glimepiride placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Met + Glim</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Glimepiride 4 mg/day + metformin 1.5-2.0 g/day + liraglutide placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>liraglutide</intervention_name>
    <description>0.6 mg for s.c. (under the skin) injection.</description>
    <arm_group_label>Lira 0.6 + Met</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>metformin</intervention_name>
    <description>1.5-2.0 g tablets</description>
    <arm_group_label>Lira 0.6 + Met</arm_group_label>
    <arm_group_label>Lira 1.2 + Met</arm_group_label>
    <arm_group_label>Lira 1.8 + Met</arm_group_label>
    <arm_group_label>Met Mono</arm_group_label>
    <arm_group_label>Met + Glim</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>glimepiride</intervention_name>
    <description>4 mg tablets</description>
    <arm_group_label>Met + Glim</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Glimepiride placebo 1 mg and 2 mg tablets</description>
    <arm_group_label>Lira 0.6 + Met</arm_group_label>
    <arm_group_label>Lira 1.2 + Met</arm_group_label>
    <arm_group_label>Lira 1.8 + Met</arm_group_label>
    <arm_group_label>Met Mono</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Liraglutide placebo 1-3 mL for s.c. (under the skin) injection</description>
    <arm_group_label>Met Mono</arm_group_label>
    <arm_group_label>Met + Glim</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>liraglutide</intervention_name>
    <description>1.2 mg for s.c. (under the skin) injection</description>
    <arm_group_label>Lira 1.2 + Met</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>liraglutide</intervention_name>
    <description>1.8 mg for s.c. (under the skin) injection</description>
    <arm_group_label>Lira 1.8 + Met</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects diagnosed with type 2 diabetes and treated with oral anti-diabetic drugs
             (OADs) for at least 3 months

          -  HbA1c: 7.0-11.0 % (both incl.) in subjects on OAD monotherapy. 7.0-10.0 % (both incl.)
             in subjects on OAD combination therapy

          -  Body Mass Index (BMI) less than or equal 40 kg/m2

        Exclusion Criteria:

          -  Subjects treated with insulin within the last three months

          -  Subjects with any serious medical condition

          -  Females of child bearing potential who are pregnant, breast-feeding or have the
             intention of becoming pregnant or not using adequate contraceptive methods

          -  Subjects using any drug (except for OADs), which in the Investigator's opinion could
             interfere with the glucose level (e.g. systemic corticosteroids)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Registry (GCR, 1452)</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Ciudad Autonoma de Bs As</city>
        <zip>C1405CWB</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Ciudad Autónoma de Bs As</city>
        <zip>C1426ABP</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Ciudad Autónoma de BsAs</city>
        <zip>C1406FWY</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Junín</city>
        <zip>6000</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Broadmeadow</city>
        <state>New South Wales</state>
        <zip>2292</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Penrith</city>
        <state>New South Wales</state>
        <zip>2751</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>St Leonards</city>
        <state>New South Wales</state>
        <zip>2065</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Daw Park</city>
        <state>South Australia</state>
        <zip>5041</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>East Ringwood</city>
        <state>Victoria</state>
        <zip>3135</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Fremantle</city>
        <state>Western Australia</state>
        <zip>6160</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Adelaide</city>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Adelaide</city>
        <zip>SA 5035</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Auckland</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Bankstown</city>
        <zip>2200</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Box Hill</city>
        <zip>3128</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Cairns</city>
        <zip>4870</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Camperdown</city>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Christchurch</city>
        <zip>8011</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Clayton</city>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Fitzroy</city>
        <zip>3065</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Garran</city>
        <zip>2605</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Hornsby</city>
        <zip>2077</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Malvern</city>
        <zip>3144</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Perth</city>
        <zip>6000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Westmead</city>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Woodville</city>
        <zip>5011</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Arlon</city>
        <zip>6700</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Bonheiden</city>
        <zip>2820</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Huy</city>
        <zip>4500</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>La Louvière</city>
        <zip>7100</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Sofia</city>
        <zip>1431</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Zagreb</city>
        <zip>10 000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Aalborg</city>
        <zip>9000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Frederiksberg</city>
        <zip>2000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Herlev</city>
        <zip>2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Hjørring</city>
        <zip>9800</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Hvidovre</city>
        <zip>2650</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>København S</city>
        <zip>2300</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>København</city>
        <zip>2400</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Odense</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Viborg</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Århus C</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Aschaffenburg</city>
        <zip>63739</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Bad Heilbrunn</city>
        <zip>83670</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Bad Kreuznach</city>
        <zip>55545</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Bad Lauterberg</city>
        <zip>37431</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Bad Mergentheim</city>
        <zip>97980</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Bad Neuenahr-Ahrweiler</city>
        <zip>53474</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Beckum</city>
        <zip>59269</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Bensheim</city>
        <zip>64625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>10115</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>12203</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>12687</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Darmstadt</city>
        <zip>64283</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Diez</city>
        <zip>65582</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Dormagen</city>
        <zip>41539</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Dresden</city>
        <zip>01219</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Flensburg</city>
        <zip>24939</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Großheirath</city>
        <zip>96269</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Halle</city>
        <zip>06114</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Hamburg</city>
        <zip>21073</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Hamburg</city>
        <zip>22607</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Kutenholz-Mulsum</city>
        <zip>27449</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Köln</city>
        <zip>50858</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Ludwigshafen</city>
        <zip>67059</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Marburg</city>
        <zip>35037</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Münster</city>
        <zip>48145</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Neuwied</city>
        <zip>56564</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Oberhausen</city>
        <zip>46145</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Pirna</city>
        <zip>01796</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Pohlheim</city>
        <zip>35415</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Regensburg</city>
        <zip>93059</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Rehlingen-Siersburg</city>
        <zip>66780</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Saaldorf-Surheim</city>
        <zip>83416</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Saarbrücken</city>
        <zip>66121</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Speyer</city>
        <zip>67346</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>St. Ingbert</city>
        <zip>66386</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Stuttgart</city>
        <zip>70184</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Sulzbach-Rosenberg</city>
        <zip>92237</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Tübingen</city>
        <zip>72072</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Viersen</city>
        <zip>41751</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Völklingen</city>
        <zip>66333</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Würzburg</city>
        <zip>97072</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Budapest</city>
        <zip>1041</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Debrecen</city>
        <zip>4043</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Gyula</city>
        <zip>5700</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Nyíregyháza</city>
        <zip>4400</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Pecs</city>
        <zip>7631</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Szekszárd</city>
        <zip>7100</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Zalaegerszeg</city>
        <zip>8900</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Hyderabad</city>
        <state>Andhra Pradesh</state>
        <zip>500082</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Kochi</city>
        <state>Kerala</state>
        <zip>682041</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Mumbai</city>
        <state>Maharashtra</state>
        <zip>400012</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Chennai</city>
        <state>Tamil Nadu</state>
        <zip>600086</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Bangalore</city>
        <zip>560034</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Dublin</city>
        <zip>DUBLIN 15</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Dublin</city>
        <zip>DUBLIN 7</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Dublin</city>
        <zip>DUBLIN 8</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Waterford</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Bari</city>
        <zip>70124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Catania</city>
        <zip>95126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Firenze</city>
        <zip>50141</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Milano</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Milano</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Monza</city>
        <zip>20052</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Orbassano</city>
        <zip>10043</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Palermo</city>
        <zip>90127</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Rimini</city>
        <zip>47900</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Roma</city>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Sassari</city>
        <zip>07100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Torino</city>
        <zip>10154</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Verona</city>
        <zip>37126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Apeldoorn</city>
        <zip>7334 DZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Groningen</city>
        <zip>9728 NT</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Rotterdam</city>
        <zip>3045 PM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Sliedrecht</city>
        <zip>3361 XV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Bekkestua</city>
        <zip>1357</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Bergen</city>
        <zip>NO-5012</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Elverum</city>
        <zip>2408</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Gjøvik</city>
        <zip>NO-2819</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Hamar</city>
        <zip>2317</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Kongsberg</city>
        <zip>NO-3602</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Kongsvinger</city>
        <zip>2212</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Stavanger</city>
        <zip>4011</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Tromsø</city>
        <zip>9038</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Trondheim</city>
        <zip>NO-7030</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Cluj Napoca</city>
        <state>Cluj</state>
        <zip>400006</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Constanta</city>
        <zip>900591</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Iasi</city>
        <zip>700111</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Moscow</city>
        <zip>117036</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Moscow</city>
        <zip>119435</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Moscow</city>
        <zip>127486</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Moscow</city>
        <zip>129090</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>194354</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>198013</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Bratislava</city>
        <zip>83 299</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Bratislava</city>
        <zip>831 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Bratislava</city>
        <zip>833 05</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Kosice</city>
        <zip>04-001</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Moldava nad Bodvou</city>
        <zip>045 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Presov</city>
        <zip>080 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Trencin</city>
        <zip>91 101</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Johannesburg</city>
        <state>Gauteng</state>
        <zip>1829</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Johannesburg</city>
        <state>Gauteng</state>
        <zip>27 11</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Durban</city>
        <state>KwaZulu-Natal</state>
        <zip>4001</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Durban</city>
        <state>KwaZulu-Natal</state>
        <zip>4091</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Durban</city>
        <state>KwaZulu-Natal</state>
        <zip>4092</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Cape Town</city>
        <state>Western Cape</state>
        <zip>7130</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Benoni</city>
        <zip>1500</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Alcazar de San Juan</city>
        <zip>13600</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Almería</city>
        <zip>04001</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08017</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Bilbao</city>
        <zip>48013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Cádiz</city>
        <zip>11009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Girona</city>
        <zip>17007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Granada</city>
        <zip>18012</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>La Coruña</city>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>La Laguna</city>
        <zip>38320</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Málaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Mérida</city>
        <zip>06800</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>San Juan</city>
        <zip>03550</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Santa Cruz de Tenerife</city>
        <zip>38010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Santander</city>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Sevilla</city>
        <zip>41009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Falun</city>
        <zip>791 82</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Karlstad</city>
        <zip>651 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Linköping</city>
        <zip>581 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Lund</city>
        <zip>221 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Malmö</city>
        <zip>205 02</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Stockholm</city>
        <zip>118 83</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Stockholm</city>
        <zip>171 76</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Umeå</city>
        <zip>901 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Abergavenny</city>
        <zip>NP7 7EG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Bath</city>
        <zip>BA1 2SR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Bath</city>
        <zip>BA2 1NH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Berkshire</city>
        <zip>RG7 3SQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Cardiff</city>
        <zip>CF23 8SQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Coventry</city>
        <zip>CV2 2DX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Dundee</city>
        <zip>DD1 9SY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>East Horsley</city>
        <zip>KT24 6QT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Frome</city>
        <zip>BA11 1EZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Llanelli</city>
        <zip>SA14 8QF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Oxford</city>
        <zip>OX3 7LE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Plymouth</city>
        <zip>PL6 8BQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Sheffield</city>
        <zip>S3 9DA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Sunbury on Thames</city>
        <zip>TW16 6RH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Bulgaria</country>
    <country>Croatia</country>
    <country>Denmark</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>India</country>
    <country>Ireland</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Slovakia</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>New Zealand</country>
  </removed_countries>
  <link>
    <url>http://novonordisk-trials.com</url>
    <description>Clinical Trials at Novo Nordisk</description>
  </link>
  <results_reference>
    <citation>Nauck M, Frid A, Hermansen K, Shah NS, Tankova T, Mitha IH, Zdravkovic M, Düring M, Matthews DR; LEAD-2 Study Group. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care. 2009 Jan;32(1):84-90. doi: 10.2337/dc08-1355. Epub 2008 Oct 17.</citation>
    <PMID>18931095</PMID>
  </results_reference>
  <results_reference>
    <citation>Sullivan SD, Alfonso-Cristancho R, Conner C, Hammer M, Blonde L. Long-term outcomes in patients with type 2 diabetes receiving glimepiride combined with liraglutide or rosiglitazone. Cardiovasc Diabetol. 2009 Feb 26;8:12. doi: 10.1186/1475-2840-8-12.</citation>
    <PMID>19245711</PMID>
  </results_reference>
  <results_reference>
    <citation>Nauck M, Marre M. Adding liraglutide to oral antidiabetic drug monotherapy: efficacy and weight benefits. Postgrad Med. 2009 May;121(3):5-15. doi: 10.3810/pgm.2009.05.1997.</citation>
    <PMID>19491535</PMID>
  </results_reference>
  <results_reference>
    <citation>McGill JB. Insights from the Liraglutide Clinical Development Program--the Liraglutide Effect and Action in Diabetes (LEAD) studies. Postgrad Med. 2009 May;121(3):16-25. doi: 10.3810/pgm.2009.05.1998. Review.</citation>
    <PMID>19491536</PMID>
  </results_reference>
  <results_reference>
    <citation>Blonde L, Russell-Jones D. The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1-5 studies. Diabetes Obes Metab. 2009 Dec;11 Suppl 3:26-34. doi: 10.1111/j.1463-1326.2009.01075.x. Review.</citation>
    <PMID>19878259</PMID>
  </results_reference>
  <results_reference>
    <citation>Jendle J, Nauck MA, Matthews DR, Frid A, Hermansen K, Düring M, Zdravkovic M, Strauss BJ, Garber AJ; LEAD-2 and LEAD-3 Study Groups. Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. Diabetes Obes Metab. 2009 Dec;11(12):1163-72. doi: 10.1111/j.1463-1326.2009.01158.x.</citation>
    <PMID>19930006</PMID>
  </results_reference>
  <results_reference>
    <citation>Buse JB, Garber A, Rosenstock J, Schmidt WE, Brett JH, Videbæk N, Holst J, Nauck M. Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events: results from the Liraglutide Effect and Action in Diabetes (LEAD) trials. J Clin Endocrinol Metab. 2011 Jun;96(6):1695-702. doi: 10.1210/jc.2010-2822. Epub 2011 Mar 30.</citation>
    <PMID>21450987</PMID>
  </results_reference>
  <results_reference>
    <citation>Bode BW, Brett J, Falahati A, Pratley RE. Comparison of the efficacy and tolerability profile of liraglutide, a once-daily human GLP-1 analog, in patients with type 2 diabetes ≥65 and &lt;65 years of age: a pooled analysis from phase III studies. Am J Geriatr Pharmacother. 2011 Dec;9(6):423-33. doi: 10.1016/j.amjopharm.2011.09.007. Epub 2011 Nov 4.</citation>
    <PMID>22055210</PMID>
  </results_reference>
  <results_reference>
    <citation>Henry RR, Buse JB, Sesti G, Davies MJ, Jensen KH, Brett J, Pratley RE. Efficacy of antihyperglycemic therapies and the influence of baseline hemoglobin A(1C): a meta-analysis of the liraglutide development program. Endocr Pract. 2011 Nov-Dec;17(6):906-13.</citation>
    <PMID>22193143</PMID>
  </results_reference>
  <results_reference>
    <citation>Zinman B, Schmidt WE, Moses A, Lund N, Gough S. Achieving a clinically relevant composite outcome of an HbA1c of &lt;7% without weight gain or hypoglycaemia in type 2 diabetes: a meta-analysis of the liraglutide clinical trial programme. Diabetes Obes Metab. 2012 Jan;14(1):77-82. doi: 10.1111/j.1463-1326.2011.01493.x. Epub 2011 Oct 30.</citation>
    <PMID>21883806</PMID>
  </results_reference>
  <results_reference>
    <citation>Davies MJ, Chubb BD, Smith IC, Valentine WJ. Cost-utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add-on to metformin monotherapy in Type 2 diabetes mellitus. Diabet Med. 2012 Mar;29(3):313-20. doi: 10.1111/j.1464-5491.2011.03429.x.</citation>
    <PMID>21883438</PMID>
  </results_reference>
  <results_reference>
    <citation>Nauck M, Frid A, Hermansen K, Thomsen AB, During M, Shah N, Tankova T, Mitha I, Matthews DR. Long-term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2-year results from the LEAD-2 study. Diabetes Obes Metab. 2013 Mar;15(3):204-12. doi: 10.1111/dom.12012. Epub 2012 Oct 11. Review.</citation>
    <PMID>22985213</PMID>
  </results_reference>
  <results_reference>
    <citation>Niswender K, Pi-Sunyer X, Buse J, Jensen KH, Toft AD, Russell-Jones D, Zinman B. Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme. Diabetes Obes Metab. 2013 Jan;15(1):42-54. doi: 10.1111/j.1463-1326.2012.01673.x. Epub 2012 Sep 9.</citation>
    <PMID>22862847</PMID>
  </results_reference>
  <results_reference>
    <citation>Alves C, Batel-Marques F, Macedo AF. A meta-analysis of serious adverse events reported with exenatide and liraglutide: acute pancreatitis and cancer. Diabetes Res Clin Pract. 2012 Nov;98(2):271-84. doi: 10.1016/j.diabres.2012.09.008. Epub 2012 Sep 23.</citation>
    <PMID>23010561</PMID>
  </results_reference>
  <results_reference>
    <citation>King AB, Montanya E, Pratley RE, Blonde L, Svendsen CB, Donsmark M, Sesti G. Liraglutide achieves A1C targets more often than sitagliptin or exenatide when added to metformin in patients with type 2 diabetes and a baseline A1C &lt;8.0%. Endocr Pract. 2013 Jan-Feb;19(1):64-72. doi: 10.4158/EP12232.OR.</citation>
    <PMID>23186975</PMID>
  </results_reference>
  <results_reference>
    <citation>Jensen TM, Saha K, Steinberg WM. Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials. Diabetes Care. 2015 Jun;38(6):1058-66. doi: 10.2337/dc13-1210. Epub 2014 Dec 12. Review. Erratum in: Diabetes Care. 2015 Aug;38(8):1622.</citation>
    <PMID>25504028</PMID>
  </results_reference>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 25, 2006</study_first_submitted>
  <study_first_submitted_qc>April 25, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 26, 2006</study_first_posted>
  <results_first_submitted>February 23, 2010</results_first_submitted>
  <results_first_submitted_qc>February 23, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 12, 2010</results_first_posted>
  <disposition_first_submitted>November 9, 2009</disposition_first_submitted>
  <disposition_first_submitted_qc>November 9, 2009</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">November 11, 2009</disposition_first_posted>
  <last_update_submitted>January 24, 2017</last_update_submitted>
  <last_update_submitted_qc>January 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glimepiride</mesh_term>
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Liraglutide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 170 centres in 21 countries: Argentina (4), Australia (19), Belgium (6), Bulgaria (1), Germany (33), Denmark (9), Spain (14), United Kingdom (11), Croatia (2), Hungary (5), Ireland (4), India (5), Italy (10), The Netherlands (5), New Zealand (3), Norway (8), Romania (3), Russia (6), Sweden (8), Slovakia (7) and South Africa (7)</recruitment_details>
      <pre_assignment_details>Eligible subjects discontinued their oral anti-diabetic drug treatment and commenced a 3-week period of forced titration of metformin followed by a 3-week maintenance period. Subjects on current metformin therapy could go through a modified titration period or advance directly to the 3-week maintenance period at the discretion of the investigator.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Lira 0.6 + Met</title>
          <description>Liraglutide 0.6 mg/day + glimepiride placebo + metformin 1.5-2.0 g/day, weeks 0-26 (double-blinded period) and open-label liraglutide 0.6 mg/day + metformin 1.5-2.0 g/day in the extension period (weeks 26-104)</description>
        </group>
        <group group_id="P2">
          <title>Lira 1.2 + Met</title>
          <description>Liraglutide 1.2 mg/day + glimepiride placebo + metformin 1.5-2.0 g/day, weeks 0-26 (double-blinded period) and open-label liraglutide 1.2 mg/day + metformin 1.5-2.0 g/day in the extension period (weeks 26-104)</description>
        </group>
        <group group_id="P3">
          <title>Lira 1.8 + Met</title>
          <description>Liraglutide 1.8 mg/day + glimepiride placebo + metformin 1.5-2.0 g/day, weeks 0-26 (double-blinded period) and open-label liraglutide 1.8 mg/day + metformin 1.5-2.0 g/day in the extension period (weeks 26-104)</description>
        </group>
        <group group_id="P4">
          <title>Met Mono</title>
          <description>Metformin 1.5-2.0 g/day + liraglutide placebo + glimepiride placebo, weeks 0-26 (double-blinded period) and open-label metformin 1.5-2.0 g/day in the extension period (weeks 26-104)</description>
        </group>
        <group group_id="P5">
          <title>Met + Glim</title>
          <description>Glimepiride 4 mg/day + metformin 1.5-2.0 g/day + liraglutide placebo, weeks 0-26 (double-blinded period) and open-label glimepiride 4 mg/day + metformin 1.5-2.0 g/day in the extension period (weeks 26-104)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Double-Blind, 6 Months</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="242">Randomised</participants>
                <participants group_id="P2" count="241">Randomised</participants>
                <participants group_id="P3" count="242">Randomised</participants>
                <participants group_id="P4" count="122">Randomised</participants>
                <participants group_id="P5" count="244">Randomised</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Exposed to Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="242"/>
                <participants group_id="P2" count="240">Subject withdrew before exposure to drug, and thus not included in the safety and ITT analysis sets</participants>
                <participants group_id="P3" count="242"/>
                <participants group_id="P4" count="121">Subject withdrew before exposure to drug, and thus not included in the safety and ITT analysis sets</participants>
                <participants group_id="P5" count="242">Subjects withdrew before exposure to drug, and thus not included in the safety and ITT analysis sets</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="208"/>
                <participants group_id="P2" count="197"/>
                <participants group_id="P3" count="191"/>
                <participants group_id="P4" count="74"/>
                <participants group_id="P5" count="210"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="44"/>
                <participants group_id="P3" count="51"/>
                <participants group_id="P4" count="48"/>
                <participants group_id="P5" count="34"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="23"/>
                <participants group_id="P3" count="29"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="13"/>
                <participants group_id="P4" count="29"/>
                <participants group_id="P5" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to follow up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Poor compliance/Non-compliance</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Consent withdrawn</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="10"/>
                <participants group_id="P5" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject decision/No wish to continue</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Move</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Tendency to low blood glucose levels</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>FPG exceeds limits/too high</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Work commitment</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Investigator decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of time</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Hypoglycaemia/Hypoglycemia</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Hyperglicaemia</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>metformin titrated &lt;1500 mg or &gt;2000 mg</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Fear of experiencing AE again</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Open-Label Extension, 18 Months</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="208"/>
                <participants group_id="P2" count="197"/>
                <participants group_id="P3" count="191"/>
                <participants group_id="P4" count="74"/>
                <participants group_id="P5" count="210"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="130"/>
                <participants group_id="P2" count="137"/>
                <participants group_id="P3" count="118"/>
                <participants group_id="P4" count="31"/>
                <participants group_id="P5" count="113"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="78"/>
                <participants group_id="P2" count="60"/>
                <participants group_id="P3" count="73"/>
                <participants group_id="P4" count="43"/>
                <participants group_id="P5" count="97"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawals between 6 and 24 months</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="27"/>
                <participants group_id="P4" count="11"/>
                <participants group_id="P5" count="22"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
                <participants group_id="P2" count="33"/>
                <participants group_id="P3" count="37"/>
                <participants group_id="P4" count="27"/>
                <participants group_id="P5" count="63"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Lira 0.6 + Met</title>
          <description>Liraglutide 0.6 mg/day + glimepiride placebo + metformin 1.5-2.0 g/day, weeks 0-26 (double-blinded period) and open-label liraglutide 0.6 mg/day + metformin 1.5-2.0 g/day in the extension period (weeks 26-104)</description>
        </group>
        <group group_id="B2">
          <title>Lira 1.2 + Met</title>
          <description>Liraglutide 1.2 mg/day + glimepiride placebo + metformin 1.5-2.0 g/day, weeks 0-26 (double-blinded period) and open-label liraglutide 1.2 mg/day + metformin 1.5-2.0 g/day in the extension period (weeks 26-104)</description>
        </group>
        <group group_id="B3">
          <title>Lira 1.8 + Met</title>
          <description>Liraglutide 1.8 mg/day + glimepiride placebo + metformin 1.5-2.0 g/day, weeks 0-26 (double-blinded period) and open-label liraglutide 1.8 mg/day + metformin 1.5-2.0 g/day in the extension period (weeks 26-104)</description>
        </group>
        <group group_id="B4">
          <title>Met Mono</title>
          <description>Metformin 1.5-2.0 g/day + liraglutide placebo + glimepiride placebo, weeks 0-26 (double-blinded period) and open-label metformin 1.5-2.0 g/day in the extension period (weeks 26-104)</description>
        </group>
        <group group_id="B5">
          <title>Met + Glim</title>
          <description>Glimepiride 4 mg/day + metformin 1.5-2.0 g/day + liraglutide placebo, weeks 0-26 (double-blinded period) and open-label glimepiride 4 mg/day + metformin 1.5-2.0 g/day in the extension period (weeks 26-104)</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="242"/>
            <count group_id="B2" value="240"/>
            <count group_id="B3" value="242"/>
            <count group_id="B4" value="121"/>
            <count group_id="B5" value="242"/>
            <count group_id="B6" value="1087"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56.0" spread="10.5"/>
                    <measurement group_id="B2" value="57.2" spread="9.2"/>
                    <measurement group_id="B3" value="56.8" spread="9.4"/>
                    <measurement group_id="B4" value="56.0" spread="9.4"/>
                    <measurement group_id="B5" value="57.3" spread="8.8"/>
                    <measurement group_id="B6" value="56.7" spread="9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="91"/>
                    <measurement group_id="B2" value="111"/>
                    <measurement group_id="B3" value="100"/>
                    <measurement group_id="B4" value="49"/>
                    <measurement group_id="B5" value="103"/>
                    <measurement group_id="B6" value="454"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="151"/>
                    <measurement group_id="B2" value="129"/>
                    <measurement group_id="B3" value="142"/>
                    <measurement group_id="B4" value="72"/>
                    <measurement group_id="B5" value="139"/>
                    <measurement group_id="B6" value="633"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="21"/>
                    <measurement group_id="B6" value="98"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="202"/>
                    <measurement group_id="B2" value="210"/>
                    <measurement group_id="B3" value="214"/>
                    <measurement group_id="B4" value="106"/>
                    <measurement group_id="B5" value="214"/>
                    <measurement group_id="B6" value="946"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Previous anti-diabetic treatment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Mono-therapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="81"/>
                    <measurement group_id="B2" value="90"/>
                    <measurement group_id="B3" value="82"/>
                    <measurement group_id="B4" value="41"/>
                    <measurement group_id="B5" value="90"/>
                    <measurement group_id="B6" value="384"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Combination therapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="161"/>
                    <measurement group_id="B2" value="150"/>
                    <measurement group_id="B3" value="160"/>
                    <measurement group_id="B4" value="80"/>
                    <measurement group_id="B5" value="152"/>
                    <measurement group_id="B6" value="703"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <description>Body Mass Index</description>
          <units>kg/m2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30.5" spread="4.8"/>
                    <measurement group_id="B2" value="31.1" spread="4.8"/>
                    <measurement group_id="B3" value="30.9" spread="4.6"/>
                    <measurement group_id="B4" value="31.6" spread="4.4"/>
                    <measurement group_id="B5" value="31.2" spread="4.6"/>
                    <measurement group_id="B6" value="31.0" spread="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration of diabetes</title>
          <description>Number of years since diagnosis of diabetes</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.0" spread="4.8"/>
                    <measurement group_id="B2" value="6.8" spread="4.9"/>
                    <measurement group_id="B3" value="7.8" spread="5.2"/>
                    <measurement group_id="B4" value="7.9" spread="6.0"/>
                    <measurement group_id="B5" value="7.7" spread="5.3"/>
                    <measurement group_id="B6" value="7.4" spread="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HbA1c</title>
          <description>Glycosylated Haemoglobin at screening</description>
          <units>percentage of total haemoglobin</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.4" spread="0.9"/>
                    <measurement group_id="B2" value="8.3" spread="0.9"/>
                    <measurement group_id="B3" value="8.3" spread="0.9"/>
                    <measurement group_id="B4" value="8.4" spread="1.0"/>
                    <measurement group_id="B5" value="8.4" spread="0.9"/>
                    <measurement group_id="B6" value="8.4" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>m</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.69" spread="0.10"/>
                    <measurement group_id="B2" value="1.68" spread="0.11"/>
                    <measurement group_id="B3" value="1.69" spread="0.10"/>
                    <measurement group_id="B4" value="1.69" spread="0.10"/>
                    <measurement group_id="B5" value="1.69" spread="0.11"/>
                    <measurement group_id="B6" value="1.69" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Glycosylated A1c (HbA1c) at Week 26</title>
        <description>Percentage point change in Glycosylated A1c (HbA1c) from baseline (week 0) to 26 weeks (end of randomisation)</description>
        <time_frame>week 0, week 26</time_frame>
        <population>Intention to treat (ITT) analysis set using LOCF (Last Observation Carried Forward) is all randomised subjects who had been exposed to at least one dose of the study products.</population>
        <group_list>
          <group group_id="O1">
            <title>Lira 0.6 + Met</title>
            <description>Liraglutide 0.6 mg/day + glimepiride placebo + metformin 1.5-2.0 g/day, weeks 0-26 (double-blinded period) and open-label liraglutide 0.6 mg/day + metformin 1.5-2.0 g/day in the extension period (weeks 26-104)</description>
          </group>
          <group group_id="O2">
            <title>Lira 1.2 + Met</title>
            <description>Liraglutide 1.2 mg/day + glimepiride placebo + metformin 1.5-2.0 g/day, weeks 0-26 (double-blinded period) and open-label liraglutide 1.2 mg/day + metformin 1.5-2.0 g/day in the extension period (weeks 26-104)</description>
          </group>
          <group group_id="O3">
            <title>Lira 1.8 + Met</title>
            <description>Liraglutide 1.8 mg/day + glimepiride placebo + metformin 1.5-2.0 g/day, weeks 0-26 (double-blinded period) and open-label liraglutide 1.8 mg/day + metformin 1.5-2.0 g/day in the extension period (weeks 26-104)</description>
          </group>
          <group group_id="O4">
            <title>Met Mono</title>
            <description>Metformin 1.5-2.0 g/day + liraglutide placebo + glimepiride placebo, weeks 0-26 (double-blinded period) and open-label metformin 1.5-2.0 g/day in the extension period (weeks 26-104)</description>
          </group>
          <group group_id="O5">
            <title>Met + Glim</title>
            <description>Glimepiride 4 mg/day + metformin 1.5-2.0 g/day + liraglutide placebo, weeks 0-26 (double-blinded period) and open-label glimepiride 4 mg/day + metformin 1.5-2.0 g/day in the extension period (weeks 26-104)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Glycosylated A1c (HbA1c) at Week 26</title>
          <description>Percentage point change in Glycosylated A1c (HbA1c) from baseline (week 0) to 26 weeks (end of randomisation)</description>
          <population>Intention to treat (ITT) analysis set using LOCF (Last Observation Carried Forward) is all randomised subjects who had been exposed to at least one dose of the study products.</population>
          <units>Percentage point of total HbA1c</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="239"/>
                <count group_id="O2" value="232"/>
                <count group_id="O3" value="236"/>
                <count group_id="O4" value="120"/>
                <count group_id="O5" value="234"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.69" spread="0.07"/>
                    <measurement group_id="O2" value="-0.97" spread="0.07"/>
                    <measurement group_id="O3" value="-1.00" spread="0.07"/>
                    <measurement group_id="O4" value="0.09" spread="0.09"/>
                    <measurement group_id="O5" value="-0.98" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Change in HbA1c from baseline to end of treatment at 26 weeks was analyzed using an analysis of covariance (ANCOVA) model with treatment, country and previous anti-diabetic treatment as fixed effects and baseline glycosylated A1c (HbA1c) as covariate.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Hypothesis testing was done in a hierarchical manner. First, it was tested whether liraglutide 1.8 mg+metformin was superior to placebo + metformin.
Superiority was always concluded if the upper limit of the 2-sided 95% CI for the treatment difference was below 0%.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Estimated treatment difference, LS Mean</param_type>
            <param_value>-1.09</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.30</ci_lower_limit>
            <ci_upper_limit>-0.88</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Change in HbA1c from baseline to end of treatment at 26 weeks was analyzed using an analysis of covariance (ANCOVA) model with treatment, country and previous anti-diabetic treatment as fixed effects and baseline glycosylated A1c (HbA1c) as covariate.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Hypothesis testing was done in a hierarchical manner. As superiority of liraglutide 1.8 mg + metformin to metformin monotherapy was established, it was investigated whether liraglutide 1.8 mg + metformin was non-inferior to glimepiride + metformin. Non-inferiority was concluded if the upper limit of the 2-sided 95% CI for the treatment difference was below 0.4%.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Estimated treatment difference, LS Mean</param_type>
            <param_value>-0.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.19</ci_lower_limit>
            <ci_upper_limit>0.15</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Change in HbA1c from baseline to end of treatment at 26 weeks was analyzed using an analysis of covariance (ANCOVA) model with treatment, country and previous anti-diabetic treatment as fixed effects and baseline glycosylated A1c (HbA1c) as covariate.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Hypothesis testing was done in a hierarchical manner. First, it was tested whether liraglutide 1.2 mg+metformin was superior to placebo + metformin. Superiority was always concluded if the upper limit of the 2-sided 95% CI for the treatment difference was below 0%.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Estimated treatment difference, LS Mean</param_type>
            <param_value>-1.06</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.27</ci_lower_limit>
            <ci_upper_limit>-0.85</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Change in HbA1c from baseline to end of treatment at 26 weeks was analyzed using an analysis of covariance (ANCOVA) model with treatment, country and previous anti-diabetic treatment as fixed effects and baseline glycosylated A1c (HbA1c) as covariate.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Hypothesis testing was done in a hierarchical manner. As superiority of liraglutide 1.2 mg + metformin to metformin monotherapy was established, it was investigated whether liraglutide 1.2 mg + metformin was non-inferior to glimepiride + metformin. Non-inferiority was concluded if the upper limit of the 2-sided 95% CI for the treatment difference was below 0.4%.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Estimated treatment difference, LS Mean</param_type>
            <param_value>0.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.16</ci_lower_limit>
            <ci_upper_limit>0.18</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Change in HbA1c from baseline to end of treatment at 26 weeks was analyzed using an analysis of covariance (ANCOVA) model with treatment, country and previous anti-diabetic treatment as fixed effects and baseline glycosylated A1c (HbA1c) as covariate.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Hypothesis testing was done in a hierarchical manner. First, it was tested whether liraglutide 0.6 mg+metformin was superior to placebo + metformin. Superiority was always concluded if the upper limit of the 2-sided 95% CI for the treatment difference was below 0%.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Estimated treatment difference, LS Mean</param_type>
            <param_value>-0.78</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.99</ci_lower_limit>
            <ci_upper_limit>-0.57</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Change in HbA1c from baseline to end of treatment at 26 weeks was analyzed using an analysis of covariance (ANCOVA) model with treatment, country and previous anti-diabetic treatment as fixed effects and baseline glycosylated A1c (HbA1c) as covariate.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Hypothesis testing was done in a hierarchical manner. As superiority of liraglutide 0.6 mg + metformin to metformin monotherapy was established, it was investigated whether liraglutide 0.6 mg + metformin was non-inferior to glimepiride + metformin. Non-inferiority was concluded if the upper limit of the 2-sided 95% CI for the treatment difference was below 0.4%.</non_inferiority_desc>
            <p_value>0.1026</p_value>
            <method>ANCOVA</method>
            <param_type>Estimated treatment difference, LS Mean</param_type>
            <param_value>0.29</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.12</ci_lower_limit>
            <ci_upper_limit>0.46</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Change in HbA1c from baseline to end of treatment at 26 weeks was analyzed using an analysis of covariance (ANCOVA) model with treatment, country and previous anti-diabetic treatment as fixed effects and baseline glycosylated A1c (HbA1c) as covariate.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>A test for superiority of glimepiride+metformin to metformin was performed to verify assay sensitivity. Superiority was always concluded if the upper limit of the 2-sided 95% CI for the treatment difference was below 0%.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Estimated treatment difference, LS Mean</param_type>
            <param_value>-1.07</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.28</ci_lower_limit>
            <ci_upper_limit>-0.86</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Body Weight at Week 26</title>
        <description>Change in body weight from baseline (week 0) to 26 weeks (end of randomisation)</description>
        <time_frame>week 0, week 26</time_frame>
        <population>Intention to treat (ITT) analysis set using LOCF (Last Observation Carried Forward) is all randomised subjects who had been exposed to at least one dose of the study products.</population>
        <group_list>
          <group group_id="O1">
            <title>Lira 0.6 + Met</title>
            <description>Liraglutide 0.6 mg/day + glimepiride placebo + metformin 1.5-2.0 g/day, weeks 0-26 (double-blinded period) and open-label liraglutide 0.6 mg/day + metformin 1.5-2.0 g/day in the extension period (weeks 26-104)</description>
          </group>
          <group group_id="O2">
            <title>Lira 1.2 + Met</title>
            <description>Liraglutide 1.2 mg/day + glimepiride placebo + metformin 1.5-2.0 g/day, weeks 0-26 (double-blinded period) and open-label liraglutide 1.2 mg/day + metformin 1.5-2.0 g/day in the extension period (weeks 26-104)</description>
          </group>
          <group group_id="O3">
            <title>Lira 1.8 + Met</title>
            <description>Liraglutide 1.8 mg/day + glimepiride placebo + metformin 1.5-2.0 g/day, weeks 0-26 (double-blinded period) and open-label liraglutide 1.8 mg/day + metformin 1.5-2.0 g/day in the extension period (weeks 26-104)</description>
          </group>
          <group group_id="O4">
            <title>Met Mono</title>
            <description>Metformin 1.5-2.0 g/day + liraglutide placebo + glimepiride placebo, weeks 0-26 (double-blinded period) and open-label metformin 1.5-2.0 g/day in the extension period (weeks 26-104)</description>
          </group>
          <group group_id="O5">
            <title>Met + Glim</title>
            <description>Glimepiride 4 mg/day + metformin 1.5-2.0 g/day + liraglutide placebo, weeks 0-26 (double-blinded period) and open-label glimepiride 4 mg/day + metformin 1.5-2.0 g/day in the extension period (weeks 26-104)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Body Weight at Week 26</title>
          <description>Change in body weight from baseline (week 0) to 26 weeks (end of randomisation)</description>
          <population>Intention to treat (ITT) analysis set using LOCF (Last Observation Carried Forward) is all randomised subjects who had been exposed to at least one dose of the study products.</population>
          <units>kg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="242"/>
                <count group_id="O2" value="236"/>
                <count group_id="O3" value="241"/>
                <count group_id="O4" value="121"/>
                <count group_id="O5" value="237"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.78" spread="0.23"/>
                    <measurement group_id="O2" value="-2.58" spread="0.24"/>
                    <measurement group_id="O3" value="-2.79" spread="0.23"/>
                    <measurement group_id="O4" value="-1.51" spread="0.31"/>
                    <measurement group_id="O5" value="0.95" spread="0.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Change in body weight from baseline to end of treatment at 26 weeks was analyzed using an analysis of covariance (ANCOVA) model with treatment, country and previous anti-diabetic treatment as fixed effects and baseline body weight as covariate.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>A two-sided 95% CI for the treatment difference between liraglutide 1.8 mg + metformin and placebo + metfomine was calculated. If the upper limit of the 95% CI was below 0%, it was concluded that the given dose of liraglutide in combination with metformin was better than the comparator therapy.</non_inferiority_desc>
            <p_value>0.0016</p_value>
            <method>ANCOVA</method>
            <param_type>Estimated treatment difference, LS Mean</param_type>
            <param_value>-1.29</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-2.16</ci_lower_limit>
            <ci_upper_limit>-0.41</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Change in body weight from baseline to end of treatment at 26 weeks was analyzed using an analysis of covariance (ANCOVA) model with treatment, country and previous anti-diabetic treatment as fixed effects and baseline body weight as covariate.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>A two-sided 95% CI for the treatment difference between liraglutide 1.8 mg + metformin and glimepiride + metfomine was calculated. If the upper limit of the 95% CI was below 0%, it was concluded that the given dose of liraglutide in combination with metformin was better than the comparator therapy.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Estimated treatment difference, LS Mean</param_type>
            <param_value>-3.75</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-4.48</ci_lower_limit>
            <ci_upper_limit>-3.01</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Change in body weight from baseline to end of treatment at 26 weeks was analyzed using an analysis of covariance (ANCOVA) model with treatment, country and previous anti-diabetic treatment as fixed effects and baseline body weight as covariate.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>A two-sided 95% CI for the treatment difference between liraglutide 1.2 mg + metformin and placebo + metfomine was calculated. If the upper limit of the 95% CI was below 0%, it was concluded that the given dose of liraglutide in combination with metformin was better than the comparator therapy.</non_inferiority_desc>
            <p_value>0.0117</p_value>
            <method>ANCOVA</method>
            <param_type>Estimated treatment difference, LS Mean</param_type>
            <param_value>-1.07</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.94</ci_lower_limit>
            <ci_upper_limit>-0.19</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Change in body weight from baseline to end of treatment at 26 weeks was analyzed using an analysis of covariance (ANCOVA) model with treatment, country and previous anti-diabetic treatment as fixed effects and baseline body weight as covariate.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>A two-sided 95% CI for the treatment difference between liraglutide 1.2 mg + metformin and glimepirde + metfomine was calculated. If the upper limit of the 95% CI was below 0%, it was concluded that the given dose of liraglutide in combination with metformin was better than the comparator therapy.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Estimated treatment difference, LS Mean</param_type>
            <param_value>-3.53</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-4.27</ci_lower_limit>
            <ci_upper_limit>-2.79</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Change in body weight from baseline to end of treatment at 26 weeks was analyzed using an analysis of covariance (ANCOVA) model with treatment, country and previous anti-diabetic treatment as fixed effects and baseline body weight as covariate.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>A two-sided 95% CI for the treatment difference between liraglutide 0.6 mg + metformin and placebo + metfomine was calculated. If the upper limit of the 95% CI was below 0%, it was concluded that the given dose of liraglutide in combination with metformin was better than the comparator therapy.</non_inferiority_desc>
            <p_value>0.8198</p_value>
            <method>ANCOVA</method>
            <param_type>Estimated treatment difference, LS Mean</param_type>
            <param_value>-0.28</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.15</ci_lower_limit>
            <ci_upper_limit>0.60</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Change in body weight from baseline to end of treatment at 26 weeks was analyzed using an analysis of covariance (ANCOVA) model with treatment, country and previous anti-diabetic treatment as fixed effects and baseline body weight as covariate.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>A two-sided 95% CI for the treatment difference between liraglutide 0.6 mg + metformin and glimepirde + metfomine was calculated. If the upper limit of the 95% CI was below 0%, it was concluded that the given dose of liraglutide in combination with metformin was better than the comparator therapy.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Estimated treatment difference, LS Mean</param_type>
            <param_value>-2.73</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-3.47</ci_lower_limit>
            <ci_upper_limit>-2.00</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Body Weight at Week 104</title>
        <description>Change in body weight from baseline (week 0) to 104 weeks (end of treatment)</description>
        <time_frame>week 0, week 104</time_frame>
        <population>Intention to treat (ITT) analysis set using LOCF (Last Observation Carried Forward) is all randomised subjects who had been exposed to at least one dose of the study products.</population>
        <group_list>
          <group group_id="O1">
            <title>Lira 0.6 + Met</title>
            <description>Liraglutide 0.6 mg/day + glimepiride placebo + metformin 1.5-2.0 g/day, weeks 0-26 (double-blinded period) and open-label liraglutide 0.6 mg/day + metformin 1.5-2.0 g/day in the extension period (weeks 26-104)</description>
          </group>
          <group group_id="O2">
            <title>Lira 1.2 + Met</title>
            <description>Liraglutide 1.2 mg/day + glimepiride placebo + metformin 1.5-2.0 g/day, weeks 0-26 (double-blinded period) and open-label liraglutide 1.2 mg/day + metformin 1.5-2.0 g/day in the extension period (weeks 26-104)</description>
          </group>
          <group group_id="O3">
            <title>Lira 1.8 + Met</title>
            <description>Liraglutide 1.8 mg/day + glimepiride placebo + metformin 1.5-2.0 g/day, weeks 0-26 (double-blinded period) and open-label liraglutide 1.8 mg/day + metformin 1.5-2.0 g/day in the extension period (weeks 26-104)</description>
          </group>
          <group group_id="O4">
            <title>Met Mono</title>
            <description>Metformin 1.5-2.0 g/day + liraglutide placebo + glimepiride placebo, weeks 0-26 (double-blinded period) and open-label metformin 1.5-2.0 g/day in the extension period (weeks 26-104)</description>
          </group>
          <group group_id="O5">
            <title>Met + Glim</title>
            <description>Glimepiride 4 mg/day + metformin 1.5-2.0 g/day + liraglutide placebo, weeks 0-26 (double-blinded period) and open-label glimepiride 4 mg/day + metformin 1.5-2.0 g/day in the extension period (weeks 26-104)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Body Weight at Week 104</title>
          <description>Change in body weight from baseline (week 0) to 104 weeks (end of treatment)</description>
          <population>Intention to treat (ITT) analysis set using LOCF (Last Observation Carried Forward) is all randomised subjects who had been exposed to at least one dose of the study products.</population>
          <units>kg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="242"/>
                <count group_id="O2" value="236"/>
                <count group_id="O3" value="241"/>
                <count group_id="O4" value="121"/>
                <count group_id="O5" value="237"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.07" spread="0.28"/>
                    <measurement group_id="O2" value="-3.03" spread="0.29"/>
                    <measurement group_id="O3" value="-2.91" spread="0.28"/>
                    <measurement group_id="O4" value="-1.80" spread="0.38"/>
                    <measurement group_id="O5" value="0.70" spread="0.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Change in body weight from baseline to end of treatment at 104 weeks was analyzed using an analysis of covariance (ANCOVA) model with treatment, country and previous anti-diabetic treatment as fixed effects and baseline body weight as covariate.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>A two-sided 95% CI for the treatment difference between liraglutide 1.8 mg + metformin and placebo + metfomine was calculated. If the upper limit of the 95% CI was below 0%, it was concluded that the given dose of liraglutide in combination with metformin was better than the comparator therapy.</non_inferiority_desc>
            <p_value>0.0378</p_value>
            <method>ANCOVA</method>
            <param_type>Estimated treatment difference, LS Mean</param_type>
            <param_value>-1.11</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-2.18</ci_lower_limit>
            <ci_upper_limit>-0.05</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Change in body weight from baseline to end of treatment at 104 weeks was analyzed using an analysis of covariance (ANCOVA) model with treatment, country and previous anti-diabetic treatment as fixed effects and baseline body weight as covariate.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>A two-sided 95% CI for the treatment difference between liraglutide 1.8 mg + metformin and glimepiride + metfomine was calculated. If the upper limit of the 95% CI was below 0%, it was concluded that the given dose of liraglutide in combination with metformin was better than the comparator therapy.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Estimated treatment difference, LS Mean</param_type>
            <param_value>-3.61</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-4.51</ci_lower_limit>
            <ci_upper_limit>-2.72</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Change in body weight from baseline to end of treatment at 104 weeks was analyzed using an analysis of covariance (ANCOVA) model with treatment, country and previous anti-diabetic treatment as fixed effects and baseline body weight as covariate.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>A two-sided 95% CI for the treatment difference between liraglutide 1.2 mg + metformin and placebo + metfomine was calculated. If the upper limit of the 95% CI was below 0%, it was concluded that the given dose of liraglutide in combination with metformin was better than the comparator therapy.</non_inferiority_desc>
            <p_value>0.0185</p_value>
            <method>ANCOVA</method>
            <param_type>Estimated treatment difference, LS Mean</param_type>
            <param_value>-1.23</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-2.30</ci_lower_limit>
            <ci_upper_limit>-0.16</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Change in body weight from baseline to end of treatment at 104 weeks was analyzed using an analysis of covariance (ANCOVA) model with treatment, country and previous anti-diabetic treatment as fixed effects and baseline body weight as covariate.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>A two-sided 95% CI for the treatment difference between liraglutide 1.2 mg + metformin and glimepirde + metfomine was calculated. If the upper limit of the 95% CI was below 0%, it was concluded that the given dose of liraglutide in combination with metformin was better than the comparator therapy.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Estimated treatment difference, LS Mean</param_type>
            <param_value>-3.73</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-4.64</ci_lower_limit>
            <ci_upper_limit>-2.83</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Change in body weight from baseline to end of treatment at 104 weeks was analyzed using an analysis of covariance (ANCOVA) model with treatment, country and previous anti-diabetic treatment as fixed effects and baseline body weight as covariate.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>A two-sided 95% CI for the treatment difference between liraglutide 0.6 mg + metformin and placebo + metfomine was calculated. If the upper limit of the 95% CI was below 0%, it was concluded that the given dose of liraglutide in combination with metformin was better than the comparator therapy.</non_inferiority_desc>
            <p_value>0.9069</p_value>
            <method>ANCOVA</method>
            <param_type>Estimated treatment difference, LS Mean</param_type>
            <param_value>-0.27</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.33</ci_lower_limit>
            <ci_upper_limit>0.80</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Change in body weight from baseline to end of treatment at 104 weeks was analyzed using an analysis of covariance (ANCOVA) model with treatment, country and previous anti-diabetic treatment as fixed effects and baseline body weight as covariate.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>A two-sided 95% CI for the treatment difference between liraglutide 0.6 mg + metformin and glimepirde + metfomine was calculated. If the upper limit of the 95% CI was below 0%, it was concluded that the given dose of liraglutide in combination with metformin was better than the comparator therapy.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Estimated treatment difference, LS Mean</param_type>
            <param_value>-2.77</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-3.67</ci_lower_limit>
            <ci_upper_limit>-1.87</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Fasting Plasma Glucose (FPG) at Week 26</title>
        <description>Change in fasting plasma glucose (FPG) from baseline (week 0) to 26 weeks (end of randomisation)</description>
        <time_frame>week 0, week 26</time_frame>
        <population>Intention to treat (ITT) analysis set using LOCF (Last Observation Carried Forward) is all randomised subjects who had been exposed to at least one dose of the study products.</population>
        <group_list>
          <group group_id="O1">
            <title>Lira 0.6 + Met</title>
            <description>Liraglutide 0.6 mg/day + glimepiride placebo + metformin 1.5-2.0 g/day, weeks 0-26 (double-blinded period) and open-label liraglutide 0.6 mg/day + metformin 1.5-2.0 g/day in the extension period (weeks 26-104)</description>
          </group>
          <group group_id="O2">
            <title>Lira 1.2 + Met</title>
            <description>Liraglutide 1.2 mg/day + glimepiride placebo + metformin 1.5-2.0 g/day, weeks 0-26 (double-blinded period) and open-label liraglutide 1.2 mg/day + metformin 1.5-2.0 g/day in the extension period (weeks 26-104)</description>
          </group>
          <group group_id="O3">
            <title>Lira 1.8 + Met</title>
            <description>Liraglutide 1.8 mg/day + glimepiride placebo + metformin 1.5-2.0 g/day, weeks 0-26 (double-blinded period) and open-label liraglutide 1.8 mg/day + metformin 1.5-2.0 g/day in the extension period (weeks 26-104)</description>
          </group>
          <group group_id="O4">
            <title>Met Mono</title>
            <description>Metformin 1.5-2.0 g/day + liraglutide placebo + glimepiride placebo, weeks 0-26 (double-blinded period) and open-label metformin 1.5-2.0 g/day in the extension period (weeks 26-104)</description>
          </group>
          <group group_id="O5">
            <title>Met + Glim</title>
            <description>Glimepiride 4 mg/day + metformin 1.5-2.0 g/day + liraglutide placebo, weeks 0-26 (double-blinded period) and open-label glimepiride 4 mg/day + metformin 1.5-2.0 g/day in the extension period (weeks 26-104)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Fasting Plasma Glucose (FPG) at Week 26</title>
          <description>Change in fasting plasma glucose (FPG) from baseline (week 0) to 26 weeks (end of randomisation)</description>
          <population>Intention to treat (ITT) analysis set using LOCF (Last Observation Carried Forward) is all randomised subjects who had been exposed to at least one dose of the study products.</population>
          <units>mmol/L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="238"/>
                <count group_id="O2" value="234"/>
                <count group_id="O3" value="235"/>
                <count group_id="O4" value="116"/>
                <count group_id="O5" value="234"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.13" spread="0.15"/>
                    <measurement group_id="O2" value="-1.63" spread="0.16"/>
                    <measurement group_id="O3" value="-1.68" spread="0.15"/>
                    <measurement group_id="O4" value="0.40" spread="0.21"/>
                    <measurement group_id="O5" value="-1.31" spread="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Change in fasting plasma glucose from baseline to end of treatment at 26 weeks was analyzed using an analysis of covariance (ANCOVA) model with treatment, country and previous anti-diabetic treatment as fixed effects and baseline fasting plasma glucose as covariate.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>A two-sided 95% CI for the treatment difference between liraglutide 1.8 mg + metformin and placebo + metfomine was calculated. If the upper limit of the 95% CI was below 0%, it was concluded that the given dose of liraglutide in combination with metformin was better than the comparator therapy.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Estimated treatment difference, LS Mean</param_type>
            <param_value>-2.09</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-2.68</ci_lower_limit>
            <ci_upper_limit>-1.50</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Change in fasting plasma glucose from baseline to end of treatment at 26 weeks was analyzed using an analysis of covariance (ANCOVA) model with treatment, country and previous anti-diabetic treatment as fixed effects and baseline fasting plasma glucose as covariate.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>A two-sided 95% CI for the treatment difference between liraglutide 1.8 mg + metformin and glimepiride + metfomine was calculated. If the upper limit of the 95% CI was below 0%, it was concluded that the given dose of liraglutide in combination with metformin was better than the comparator therapy.</non_inferiority_desc>
            <p_value>0.1845</p_value>
            <method>ANCOVA</method>
            <param_type>Estimated treatment difference, LS Mean</param_type>
            <param_value>-0.38</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.87</ci_lower_limit>
            <ci_upper_limit>0.11</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Change in fasting plasma glucose from baseline to end of treatment at 26 weeks was analyzed using an analysis of covariance (ANCOVA) model with treatment, country and previous anti-diabetic treatment as fixed effects and baseline fasting plasma glucose as covariate.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>A two-sided 95% CI for the treatment difference between liraglutide 1.2 mg + metformin and placebo + metfomine was calculated. If the upper limit of the 95% CI was below 0%, it was concluded that the given dose of liraglutide in combination with metformin was better than the comparator therapy.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Estimated treatment difference, LS Mean</param_type>
            <param_value>-2.04</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-2.63</ci_lower_limit>
            <ci_upper_limit>-1.44</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Change in fasting plasma glucose from baseline to end of treatment at 26 weeks was analyzed using an analysis of covariance (ANCOVA) model with treatment, country and previous anti-diabetic treatment as fixed effects and baseline fasting plasma glucose t as covariate.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>A two-sided 95% CI for the treatment difference between liraglutide 1.2 mg + metformin and glimepirde + metfomine was calculated. If the upper limit of the 95% CI was below 0%, it was concluded that the given dose of liraglutide in combination with metformin was better than the comparator therapy.</non_inferiority_desc>
            <p_value>0.3047</p_value>
            <method>ANCOVA</method>
            <param_type>Estimated treatment difference, LS Mean</param_type>
            <param_value>-0.33</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.82</ci_lower_limit>
            <ci_upper_limit>0.17</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Change in fasting plasma glucose from baseline to end of treatment at 26 weeks was analyzed using an analysis of covariance (ANCOVA) model with treatment, country and previous anti-diabetic treatment as fixed effects and baseline fasting plasma glucose as covariate.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>A two-sided 95% CI for the treatment difference between liraglutide 0.6 mg + metformin and placebo + metfomine was calculated. If the upper limit of the 95% CI was below 0%, it was concluded that the given dose of liraglutide in combination with metformin was better than the comparator therapy.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Estimated treatment difference, LS Mean</param_type>
            <param_value>-1.53</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-2.12</ci_lower_limit>
            <ci_upper_limit>-0.94</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Change in fasting plasma glucose from baseline to end of treatment at 26 weeks was analyzed using an analysis of covariance (ANCOVA) model with treatment, country and previous anti-diabetic treatment as fixed effects and baseline fasting plasma glucose as covariate.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>A two-sided 95% CI for the treatment difference between liraglutide 0.6 mg + metformin and glimepirde + metfomine was calculated. If the upper limit of the 95% CI was below 0%, it was concluded that the given dose of liraglutide in combination with metformin was better than the comparator therapy.</non_inferiority_desc>
            <p_value>0.8079</p_value>
            <method>ANCOVA</method>
            <param_type>Estimated treatment difference, LS Mean</param_type>
            <param_value>0.18</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.32</ci_lower_limit>
            <ci_upper_limit>0.67</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Fasting Plasma Glucose (FPG) at Week 104</title>
        <description>Change in Fasting plasma glucose (FPG) from baseline (week 0) to 104 weeks (end of treatment)</description>
        <time_frame>week 0, week 104</time_frame>
        <population>Intention to treat (ITT) analysis set using LOCF (Last Observation Carried Forward) is all randomised subjects who had been exposed to at least one dose of the study products.</population>
        <group_list>
          <group group_id="O1">
            <title>Lira 0.6 + Met</title>
            <description>Liraglutide 0.6 mg/day + glimepiride placebo + metformin 1.5-2.0 g/day, weeks 0-26 (double-blinded period) and open-label liraglutide 0.6 mg/day + metformin 1.5-2.0 g/day in the extension period (weeks 26-104)</description>
          </group>
          <group group_id="O2">
            <title>Lira 1.2 + Met</title>
            <description>Liraglutide 1.2 mg/day + glimepiride placebo + metformin 1.5-2.0 g/day, weeks 0-26 (double-blinded period) and open-label liraglutide 1.2 mg/day + metformin 1.5-2.0 g/day in the extension period (weeks 26-104)</description>
          </group>
          <group group_id="O3">
            <title>Lira 1.8 + Met</title>
            <description>Liraglutide 1.8 mg/day + glimepiride placebo + metformin 1.5-2.0 g/day, weeks 0-26 (double-blinded period) and open-label liraglutide 1.8 mg/day + metformin 1.5-2.0 g/day in the extension period (weeks 26-104)</description>
          </group>
          <group group_id="O4">
            <title>Met Mono</title>
            <description>Metformin 1.5-2.0 g/day + liraglutide placebo + glimepiride placebo, weeks 0-26 (double-blinded period) and open-label metformin 1.5-2.0 g/day in the extension period (weeks 26-104)</description>
          </group>
          <group group_id="O5">
            <title>Met + Glim</title>
            <description>Glimepiride 4 mg/day + metformin 1.5-2.0 g/day + liraglutide placebo, weeks 0-26 (double-blinded period) and open-label glimepiride 4 mg/day + metformin 1.5-2.0 g/day in the extension period (weeks 26-104)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Fasting Plasma Glucose (FPG) at Week 104</title>
          <description>Change in Fasting plasma glucose (FPG) from baseline (week 0) to 104 weeks (end of treatment)</description>
          <population>Intention to treat (ITT) analysis set using LOCF (Last Observation Carried Forward) is all randomised subjects who had been exposed to at least one dose of the study products.</population>
          <units>mmol/L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="238"/>
                <count group_id="O2" value="233"/>
                <count group_id="O3" value="234"/>
                <count group_id="O4" value="116"/>
                <count group_id="O5" value="234"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.80" spread="0.17"/>
                    <measurement group_id="O2" value="-1.20" spread="0.18"/>
                    <measurement group_id="O3" value="-1.18" spread="0.17"/>
                    <measurement group_id="O4" value="0.75" spread="0.23"/>
                    <measurement group_id="O5" value="-0.64" spread="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Change in fasting plasma glucose from baseline to end of treatment at 104 weeks was analyzed using an analysis of covariance (ANCOVA) model with treatment, country and previous anti-diabetic treatment as fixed effects and baseline fasting plasma glucose as covariate.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>A two-sided 95% CI for the treatment difference between liraglutide 1.8 mg + metformin and placebo + metfomine was calculated. If the upper limit of the 95% CI was below 0%, it was concluded that the given dose of liraglutide in combination with metformin was better than the comparator therapy.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Estimated treatment difference, LS Mean</param_type>
            <param_value>-1.93</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-2.58</ci_lower_limit>
            <ci_upper_limit>-1.28</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Change in fasting plasma glucose from baseline to end of treatment at 104 weeks was analyzed using an analysis of covariance (ANCOVA) model with treatment, country and previous anti-diabetic treatment as fixed effects and baseline fasting plasma glucose as covariate.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>A two-sided 95% CI for the treatment difference between liraglutide 1.8 mg + metformin and glimepiride + metfomine was calculated. If the upper limit of the 95% CI was below 0%, it was concluded that the given dose of liraglutide in combination with metformin was better than the comparator therapy.</non_inferiority_desc>
            <p_value>0.0542</p_value>
            <method>ANCOVA</method>
            <param_type>Estimated treatment difference, LS Mean</param_type>
            <param_value>-0.53</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.08</ci_lower_limit>
            <ci_upper_limit>0.01</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Change in fasting plasma glucose from baseline to end of treatment at 104 weeks was analyzed using an analysis of covariance (ANCOVA) model with treatment, country and previous anti-diabetic treatment as fixed effects and baseline fasting plasma glucose as covariate.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>A two-sided 95% CI for the treatment difference between liraglutide 1.2 mg + metformin and placebo + metfomine was calculated. If the upper limit of the 95% CI was below 0%, it was concluded that the given dose of liraglutide in combination with metformin was better than the comparator therapy.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Estimated treatment difference, LS Mean</param_type>
            <param_value>-1.95</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-2.60</ci_lower_limit>
            <ci_upper_limit>-1.30</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Change in fasting plasma glucose from baseline to end of treatment at 104 weeks was analyzed using an analysis of covariance (ANCOVA) model with treatment, country and previous anti-diabetic treatment as fixed effects and baseline fasting plasma glucose t as covariate.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>A two-sided 95% CI for the treatment difference between liraglutide 1.2 mg + metformin and glimepirde + metfomine was calculated. If the upper limit of the 95% CI was below 0%, it was concluded that the given dose of liraglutide in combination with metformin was better than the comparator therapy.</non_inferiority_desc>
            <p_value>0.0451</p_value>
            <method>ANCOVA</method>
            <param_type>Estimated treatment difference, LS Mean</param_type>
            <param_value>-0.55</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.10</ci_lower_limit>
            <ci_upper_limit>-0.01</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Change in fasting plasma glucose from baseline to end of treatment at 104 weeks was analyzed using an analysis of covariance (ANCOVA) model with treatment, country and previous anti-diabetic treatment as fixed effects and baseline fasting plasma glucose as covariate.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>A two-sided 95% CI for the treatment difference between liraglutide 0.6 mg + metformin and placebo + metfomine was calculated. If the upper limit of the 95% CI was below 0%, it was concluded that the given dose of liraglutide in combination with metformin was better than the comparator therapy.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Estimated treatment difference, LS Mean</param_type>
            <param_value>-1.55</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-2.20</ci_lower_limit>
            <ci_upper_limit>-0.90</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Change in fasting plasma glucose from baseline to end of treatment at 104 weeks was analyzed using an analysis of covariance (ANCOVA) model with treatment, country and previous anti-diabetic treatment as fixed effects and baseline fasting plasma glucose as covariate.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>A two-sided 95% CI for the treatment difference between liraglutide 0.6 mg + metformin and glimepirde + metfomine was calculated. If the upper limit of the 95% CI was below 0%, it was concluded that the given dose of liraglutide in combination with metformin was better than the comparator therapy.</non_inferiority_desc>
            <p_value>0.9006</p_value>
            <method>ANCOVA</method>
            <param_type>Estimated treatment difference, LS Mean</param_type>
            <param_value>-0.15</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.70</ci_lower_limit>
            <ci_upper_limit>0.39</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Mean Prandial Increments of Plasma Glucose Based on Self-measured 7-point Plasma Glucose Profiles at Week 26</title>
        <description>Change in mean prandial increments of plasma glucose based on self-measured 7-point plasma glucose profiles from baseline (week 0) to 26 weeks (end of randomisation). The 7 time points for self-measurements were: before each meal (breakfast, lunch and dinner), at 90 min after start of each meal (breakfast, lunch and dinner) and at bedtime.
Mean prandial increments of plasma glucose were calculated as the sum of the plasma glucose differences between values measured before and after a meal (breakfast, lunch and dinner) divided by three.</description>
        <time_frame>week 0, week 26</time_frame>
        <population>Intention to treat (ITT) analysis set using LOCF (Last Observation Carried Forward) is all randomised subjects who had been exposed to at least one dose of the study products.</population>
        <group_list>
          <group group_id="O1">
            <title>Lira 0.6 + Met</title>
            <description>Liraglutide 0.6 mg/day + glimepiride placebo + metformin 1.5-2.0 g/day, weeks 0-26 (double-blinded period) and open-label liraglutide 0.6 mg/day + metformin 1.5-2.0 g/day in the extension period (weeks 26-104)</description>
          </group>
          <group group_id="O2">
            <title>Lira 1.2 + Met</title>
            <description>Liraglutide 1.2 mg/day + glimepiride placebo + metformin 1.5-2.0 g/day, weeks 0-26 (double-blinded period) and open-label liraglutide 1.2 mg/day + metformin 1.5-2.0 g/day in the extension period (weeks 26-104)</description>
          </group>
          <group group_id="O3">
            <title>Lira 1.8 + Met</title>
            <description>Liraglutide 1.8 mg/day + glimepiride placebo + metformin 1.5-2.0 g/day, weeks 0-26 (double-blinded period) and open-label liraglutide 1.8 mg/day + metformin 1.5-2.0 g/day in the extension period (weeks 26-104)</description>
          </group>
          <group group_id="O4">
            <title>Met Mono</title>
            <description>Metformin 1.5-2.0 g/day + liraglutide placebo + glimepiride placebo, weeks 0-26 (double-blinded period) and open-label metformin 1.5-2.0 g/day in the extension period (weeks 26-104)</description>
          </group>
          <group group_id="O5">
            <title>Met + Glim</title>
            <description>Glimepiride 4 mg/day + metformin 1.5-2.0 g/day + liraglutide placebo, weeks 0-26 (double-blinded period) and open-label glimepiride 4 mg/day + metformin 1.5-2.0 g/day in the extension period (weeks 26-104)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Mean Prandial Increments of Plasma Glucose Based on Self-measured 7-point Plasma Glucose Profiles at Week 26</title>
          <description>Change in mean prandial increments of plasma glucose based on self-measured 7-point plasma glucose profiles from baseline (week 0) to 26 weeks (end of randomisation). The 7 time points for self-measurements were: before each meal (breakfast, lunch and dinner), at 90 min after start of each meal (breakfast, lunch and dinner) and at bedtime.
Mean prandial increments of plasma glucose were calculated as the sum of the plasma glucose differences between values measured before and after a meal (breakfast, lunch and dinner) divided by three.</description>
          <population>Intention to treat (ITT) analysis set using LOCF (Last Observation Carried Forward) is all randomised subjects who had been exposed to at least one dose of the study products.</population>
          <units>mmol/l</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="214"/>
                <count group_id="O2" value="207"/>
                <count group_id="O3" value="205"/>
                <count group_id="O4" value="90"/>
                <count group_id="O5" value="213"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.23" spread="0.12"/>
                    <measurement group_id="O2" value="-0.40" spread="0.13"/>
                    <measurement group_id="O3" value="-0.56" spread="0.12"/>
                    <measurement group_id="O4" value="-0.44" spread="0.18"/>
                    <measurement group_id="O5" value="-0.44" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Change in prandial increments of plasma glucose from baseline to 26 weeks of treatment was analyzed using an analysis of covariance (ANCOVA) model with treatment, country and previous anti-diabetic treatment as fixed effects and baseline value as covariate.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>A two-sided 95% CI for the treatment difference between liraglutide 1.8 mg + metformin and placebo + metfomine was calculated. If the upper limit of the 95% CI was below 0%, it was concluded that the given dose of liraglutide in combination with metformin was better than the comparator therapy.</non_inferiority_desc>
            <p_value>0.8871</p_value>
            <method>ANCOVA</method>
            <param_type>Estimated treatment difference, LS Mean</param_type>
            <param_value>-0.13</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.62</ci_lower_limit>
            <ci_upper_limit>0.36</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Change in prandial increments of plasma glucose from baseline to 26 weeks of treatment was analyzed using an analysis of covariance (ANCOVA) model with treatment, country and previous anti-diabetic treatment as fixed effects and baseline value as covariate.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>A two-sided 95% CI for the treatment difference between liraglutide 1.8 mg + metformin and glimepiride + metfomine was calculated. If the upper limit of the 95% CI was below 0%, it was concluded that the given dose of liraglutide in combination with metformin was better than the comparator therapy.</non_inferiority_desc>
            <p_value>0.8695</p_value>
            <method>ANCOVA</method>
            <param_type>Estimated treatment difference, LS Mean</param_type>
            <param_value>-0.12</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.51</ci_lower_limit>
            <ci_upper_limit>0.27</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Change in prandial increments of plasma glucose from baseline to 26 weeks of treatment was analyzed using an analysis of covariance (ANCOVA) model with treatment, country and previous anti-diabetic treatment as fixed effects and baseline value as covariate.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>A two-sided 95% CI for the treatment difference between liraglutide 1.2 mg + metformin and placebo + metfomine was calculated. If the upper limit of the 95% CI was below 0%, it was concluded that the given dose of liraglutide in combination with metformin was better than the comparator therapy.</non_inferiority_desc>
            <p_value>0.9994</p_value>
            <method>ANCOVA</method>
            <param_type>Estimated treatment difference, LS Mean</param_type>
            <param_value>0.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.46</ci_lower_limit>
            <ci_upper_limit>0.52</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Change in prandial increments of plasma glucose from baseline to 26 weeks of treatment was analyzed using an analysis of covariance (ANCOVA) model with treatment, country and previous anti-diabetic treatment as fixed effects and baseline value as covariate.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>A two-sided 95% CI for the treatment difference between liraglutide 1.2 mg + metformin and glimepirde + metfomine was calculated. If the upper limit of the 95% CI was below 0%, it was concluded that the given dose of liraglutide in combination with metformin was better than the comparator therapy.</non_inferiority_desc>
            <p_value>0.9984</p_value>
            <method>ANCOVA</method>
            <param_type>Estimated treatment difference, LS Mean</param_type>
            <param_value>0.04</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.35</ci_lower_limit>
            <ci_upper_limit>0.43</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Change in mean prandial increments of plasma glucose from baseline to 26 weeks of treatment was analyzed using an analysis of covariance (ANCOVA) model with treatment, country and previous anti-diabetic treatment as fixed effects and baseline value as covariate.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>A two-sided 95% CI for the treatment difference between liraglutide 0.6 mg + metformin and placebo + metfomine was calculated. If the upper limit of the 95% CI was below 0%, it was concluded that the given dose of liraglutide in combination with metformin was better than the comparator therapy.</non_inferiority_desc>
            <p_value>0.6201</p_value>
            <method>ANCOVA</method>
            <param_type>Estimated treatment difference, LS Mean</param_type>
            <param_value>0.21</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.28</ci_lower_limit>
            <ci_upper_limit>0.70</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Change in mean prandial increments of plasma glucose from baseline to 26 weeks of treatment was analyzed using an analysis of covariance (ANCOVA) model with treatment, country and previous anti-diabetic treatment as fixed effects and baseline value as covariate.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>A two-sided 95% CI for the treatment difference between liraglutide 0.6 mg + metformin and glimepirde + metfomine was calculated. If the upper limit of the 95% CI was below 0%, it was concluded that the given dose of liraglutide in combination with metformin was better than the comparator therapy.</non_inferiority_desc>
            <p_value>0.4831</p_value>
            <method>ANCOVA</method>
            <param_type>Estimated treatment difference, LS Mean</param_type>
            <param_value>0.21</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.18</ci_lower_limit>
            <ci_upper_limit>0.60</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Glycosylated A1c (HbA1c) at Week 104</title>
        <description>Change in glycosylated A1c (HbA1c) baseline (week 0) to 104 weeks (end of randomisation)</description>
        <time_frame>week 0, week 104</time_frame>
        <population>Intention to treat (ITT) analysis set using LOCF (Last Observation Carried Forward) is all randomised subjects who had been exposed to at least one dose of the study products.</population>
        <group_list>
          <group group_id="O1">
            <title>Lira 0.6 + Met</title>
            <description>Liraglutide 0.6 mg/day + glimepiride placebo + metformin 1.5-2.0 g/day, weeks 0-26 (double-blinded period) and open-label liraglutide 0.6 mg/day + metformin 1.5-2.0 g/day in the extension period (weeks 26-104)</description>
          </group>
          <group group_id="O2">
            <title>Lira 1.2 + Met</title>
            <description>Liraglutide 1.2 mg/day + glimepiride placebo + metformin 1.5-2.0 g/day, weeks 0-26 (double-blinded period) and open-label liraglutide 1.2 mg/day + metformin 1.5-2.0 g/day in the extension period (weeks 26-104)</description>
          </group>
          <group group_id="O3">
            <title>Lira 1.8 + Met</title>
            <description>Liraglutide 1.8 mg/day + glimepiride placebo + metformin 1.5-2.0 g/day, weeks 0-26 (double-blinded period) and open-label liraglutide 1.8 mg/day + metformin 1.5-2.0 g/day in the extension period (weeks 26-104)</description>
          </group>
          <group group_id="O4">
            <title>Met Mono</title>
            <description>Metformin 1.5-2.0 g/day + liraglutide placebo + glimepiride placebo, weeks 0-26 (double-blinded period) and open-label metformin 1.5-2.0 g/day in the extension period (weeks 26-104)</description>
          </group>
          <group group_id="O5">
            <title>Met + Glim</title>
            <description>Glimepiride 4 mg/day + metformin 1.5-2.0 g/day + liraglutide placebo, weeks 0-26 (double-blinded period) and open-label glimepiride 4 mg/day + metformin 1.5-2.0 g/day in the extension period (weeks 26-104)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Glycosylated A1c (HbA1c) at Week 104</title>
          <description>Change in glycosylated A1c (HbA1c) baseline (week 0) to 104 weeks (end of randomisation)</description>
          <population>Intention to treat (ITT) analysis set using LOCF (Last Observation Carried Forward) is all randomised subjects who had been exposed to at least one dose of the study products.</population>
          <units>percentage of total haemoglobin</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="239"/>
                <count group_id="O2" value="231"/>
                <count group_id="O3" value="235"/>
                <count group_id="O4" value="120"/>
                <count group_id="O5" value="234"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.36" spread="0.08"/>
                    <measurement group_id="O2" value="-0.56" spread="0.08"/>
                    <measurement group_id="O3" value="-0.58" spread="0.08"/>
                    <measurement group_id="O4" value="0.25" spread="0.10"/>
                    <measurement group_id="O5" value="-0.50" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Change in HbA1c from baseline to end of treatment at 104 weeks was analyzed using an analysis of covariance (ANCOVA) model with treatment, country and previous anti-diabetic treatment as fixed effects and baseline glycosylated A1c (HbA1c) as covariate.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Hypothesis testing was done in a hierarchical manner. First, it was tested whether liraglutide 1.8 mg+metformin was superior to placebo + metformin. Superiority was always concluded if the upper limit of the 2-sided 95% CI for the treatment difference was below 0%.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Estimated treatment difference, LS Mean</param_type>
            <param_value>-0.83</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.07</ci_lower_limit>
            <ci_upper_limit>-0.59</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Change in HbA1c from baseline to end of treatment at 104 weeks was analyzed using an analysis of covariance (ANCOVA) model with treatment, country and previous anti-diabetic treatment as fixed effects and baseline glycosylated A1c (HbA1c) as covariate.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Hypothesis testing was done in a hierarchical manner. As superiority of liraglutide 1.8 mg + metformin to metformin monotherapy was established, it was investigated whether liraglutide 1.8 mg + metformin was non-inferior to glimepiride + metformin. Non-inferiority was concluded if the upper limit of the 2-sided 95% CI for the treatment difference was below 0.4%.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Estimated treatment difference, LS Mean</param_type>
            <param_value>-0.08</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.28</ci_lower_limit>
            <ci_upper_limit>0.12</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Change in HbA1c from baseline to end of treatment was at 104 weeks analyzed using an analysis of covariance (ANCOVA) model with treatment, country and previous anti-diabetic treatment as fixed effects and baseline glycosylated A1c (HbA1c) as covariate.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Hypothesis testing was done in a hierarchical manner. First, it was tested whether liraglutide 1.2 mg+metformin was superior to placebo + metformin. Superiority was always concluded if the upper limit of the 2-sided 95% CI for the treatment difference was below 0%.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Estimated treatment difference, LS Mean</param_type>
            <param_value>-0.81</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.05</ci_lower_limit>
            <ci_upper_limit>-0.57</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Change in HbA1c from baseline to end of treatment at 104 weeks was analyzed using an analysis of covariance (ANCOVA) model with treatment, country and previous anti-diabetic treatment as fixed effects and baseline glycosylated A1c (HbA1c) as covariate.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Hypothesis testing was done in a hierarchical manner. As superiority of liraglutide 1.2 mg + metformin to metformin monotherapy was established, it was investigated whether liraglutide 1.2 mg + metformin was non-inferior to glimepiride + metformin. Non-inferiority was concluded if the upper limit of the 2-sided 95% CI for the treatment difference was below 0.4%.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Estimated treatment difference, LS Mean</param_type>
            <param_value>-0.07</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.27</ci_lower_limit>
            <ci_upper_limit>0.13</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Change in HbA1c from baseline to end of treatment at 104 weeks was analyzed using an analysis of covariance (ANCOVA) model with treatment, country and previous anti-diabetic treatment as fixed effects and baseline glycosylated A1c (HbA1c) as covariate.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Hypothesis testing was done in a hierarchical manner. First, it was tested whether liraglutide 0.6 mg+metformin was superior to placebo + metformin.
Superiority was always concluded if the upper limit of the 2-sided 95% CI for the treatment difference was below 0%.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Estimated treatment difference, LS Mean</param_type>
            <param_value>-0.61</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.85</ci_lower_limit>
            <ci_upper_limit>-0.37</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Change in HbA1c from baseline to end of treatment at 104 weeks was analyzed using an analysis of covariance (ANCOVA) model with treatment, country and previous anti-diabetic treatment as fixed effects and baseline glycosylated A1c (HbA1c) as covariate.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Hypothesis testing was done in a hierarchical manner. As superiority of liraglutide 0.6 mg + metformin to metformin monotherapy was established, it was investigated whether liraglutide 0.6 mg + metformin was non-inferior to glimepiride + metformin. Non-inferiority was concluded if the upper limit of the 2-sided 95% CI for the treatment difference was below 0.4%.</non_inferiority_desc>
            <p_value>0.0052</p_value>
            <method>ANCOVA</method>
            <param_type>Estimated treatment difference, LS Mean</param_type>
            <param_value>0.14</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.06</ci_lower_limit>
            <ci_upper_limit>0.34</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Change in HbA1c from baseline to end of treatment at 104 weeks was analyzed using an analysis of covariance (ANCOVA) model with treatment, country and previous anti-diabetic treatment as fixed effects and baseline glycosylated A1c (HbA1c) as covariate.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>A test for superiority of glimepiride+metformin to placebo metformin was performed to verify assay sensitivity. Superiority was always concluded if the upper limit of the 2-sided 95% CI for the treatment difference was below 0%.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Estimated treatment difference, LS Mean</param_type>
            <param_value>-0.75</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.99</ci_lower_limit>
            <ci_upper_limit>-0.51</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Mean Prandial Increments of Plasma Glucose Based on Self-measured 7-point Plasma Glucose Profiles at Week 104</title>
        <description>Change in mean prandial increments of plasma glucose based on self-measured 7-point plasma glucose profiles from baseline (week 0) to 104 weeks (end of treatment). The 7 time points for self-measurements were: before each meal (breakfast, lunch and dinner), at 90 min after start of each meal (breakfast, lunch and dinner) and at bedtime.
Mean prandial increments of plasma glucose were calculated as the sum of the plasma glucose differences between values measured before and after a meal (breakfast, lunch and dinner) divided by three.</description>
        <time_frame>week 0, week 104</time_frame>
        <population>Intention to treat (ITT) analysis set using LOCF (Last Observation Carried Forward) is all randomised subjects who had been exposed to at least one dose of the study products.</population>
        <group_list>
          <group group_id="O1">
            <title>Lira 0.6 + Met</title>
            <description>Liraglutide 0.6 mg/day + glimepiride placebo + metformin 1.5-2.0 g/day, weeks 0-26 (double-blinded period) and open-label liraglutide 0.6 mg/day + metformin 1.5-2.0 g/day in the extension period (weeks 26-104)</description>
          </group>
          <group group_id="O2">
            <title>Lira 1.2 + Met</title>
            <description>Liraglutide 1.2 mg/day + glimepiride placebo + metformin 1.5-2.0 g/day, weeks 0-26 (double-blinded period) and open-label liraglutide 1.2 mg/day + metformin 1.5-2.0 g/day in the extension period (weeks 26-104)</description>
          </group>
          <group group_id="O3">
            <title>Lira 1.8 + Met</title>
            <description>Liraglutide 1.8 mg/day + glimepiride placebo + metformin 1.5-2.0 g/day, weeks 0-26 (double-blinded period) and open-label liraglutide 1.8 mg/day + metformin 1.5-2.0 g/day in the extension period (weeks 26-104)</description>
          </group>
          <group group_id="O4">
            <title>Met Mono</title>
            <description>Metformin 1.5-2.0 g/day + liraglutide placebo + glimepiride placebo, weeks 0-26 (double-blinded period) and open-label metformin 1.5-2.0 g/day in the extension period (weeks 26-104)</description>
          </group>
          <group group_id="O5">
            <title>Met + Glim</title>
            <description>Glimepiride 4 mg/day + metformin 1.5-2.0 g/day + liraglutide placebo, weeks 0-26 (double-blinded period) and open-label glimepiride 4 mg/day + metformin 1.5-2.0 g/day in the extension period (weeks 26-104)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Mean Prandial Increments of Plasma Glucose Based on Self-measured 7-point Plasma Glucose Profiles at Week 104</title>
          <description>Change in mean prandial increments of plasma glucose based on self-measured 7-point plasma glucose profiles from baseline (week 0) to 104 weeks (end of treatment). The 7 time points for self-measurements were: before each meal (breakfast, lunch and dinner), at 90 min after start of each meal (breakfast, lunch and dinner) and at bedtime.
Mean prandial increments of plasma glucose were calculated as the sum of the plasma glucose differences between values measured before and after a meal (breakfast, lunch and dinner) divided by three.</description>
          <population>Intention to treat (ITT) analysis set using LOCF (Last Observation Carried Forward) is all randomised subjects who had been exposed to at least one dose of the study products.</population>
          <units>mmol/L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="218"/>
                <count group_id="O2" value="208"/>
                <count group_id="O3" value="206"/>
                <count group_id="O4" value="90"/>
                <count group_id="O5" value="215"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.27" spread="0.12"/>
                    <measurement group_id="O2" value="-0.56" spread="0.13"/>
                    <measurement group_id="O3" value="-0.44" spread="0.13"/>
                    <measurement group_id="O4" value="-0.20" spread="0.18"/>
                    <measurement group_id="O5" value="-0.29" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Change in prandial increments of plasma glucose from baseline to 104 weeks of treatment was analyzed using an analysis of covariance (ANCOVA) model with treatment, country and previous anti-diabetic treatment as fixed effects and baseline value as covariate.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>A two-sided 95% CI for the treatment difference between liraglutide 1.8 mg + metformin and placebo + metfomine was calculated. If the upper limit of the 95% CI was below 0%, it was concluded that the given dose of liraglutide in combination with metformin was better than the comparator therapy.</non_inferiority_desc>
            <p_value>0.5282</p_value>
            <method>ANCOVA</method>
            <param_type>Estimated treatment difference, LS Mean</param_type>
            <param_value>-0.24</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.74</ci_lower_limit>
            <ci_upper_limit>0.26</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Change in prandial increments of plasma glucose from baseline to 104 weeks of treatment was analyzed using an analysis of covariance (ANCOVA) model with treatment, country and previous anti-diabetic treatment as fixed effects and baseline value as covariate.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>A two-sided 95% CI for the treatment difference between liraglutide 1.8 mg + metformin and glimepiride + metfomine was calculated. If the upper limit of the 95% CI was below 0%, it was concluded that the given dose of liraglutide in combination with metformin was better than the comparator therapy.</non_inferiority_desc>
            <p_value>0.7644</p_value>
            <method>ANCOVA</method>
            <param_type>Estimated treatment difference, LS Mean</param_type>
            <param_value>-0.15</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.55</ci_lower_limit>
            <ci_upper_limit>0.25</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Change in prandial increments of plasma glucose from baseline to 104 weeks of treatment was analyzed using an analysis of covariance (ANCOVA) model with treatment, country and previous anti-diabetic treatment as fixed effects and baseline value as covariate.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>A two-sided 95% CI for the treatment difference between liraglutide 1.2 mg + metformin and placebo + metfomine was calculated. If the upper limit of the 95% CI was below 0%, it was concluded that the given dose of liraglutide in combination with metformin was better than the comparator therapy.</non_inferiority_desc>
            <p_value>0.2063</p_value>
            <method>ANCOVA</method>
            <param_type>Estimated treatment difference, LS Mean</param_type>
            <param_value>-0.36</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.86</ci_lower_limit>
            <ci_upper_limit>0.14</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Change in prandial increments of plasma glucose from baseline to 104 weeks of treatment was analyzed using an analysis of covariance (ANCOVA) model with treatment, country and previous anti-diabetic treatment as fixed effects and baseline value as covariate.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>A two-sided 95% CI for the treatment difference between liraglutide 1.2 mg + metformin and glimepirde + metfomine was calculated. If the upper limit of the 95% CI was below 0%, it was concluded that the given dose of liraglutide in combination with metformin was better than the comparator therapy.</non_inferiority_desc>
            <p_value>0.2678</p_value>
            <method>ANCOVA</method>
            <param_type>Estimated treatment difference, LS Mean</param_type>
            <param_value>-0.28</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.68</ci_lower_limit>
            <ci_upper_limit>0.12</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Change in prandial increments of plasma glucose from baseline to 104 weeks of treatment was analyzed using an analysis of covariance (ANCOVA) model with treatment, country and previous anti-diabetic treatment as fixed effects and baseline value as covariate.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>A two-sided 95% CI for the treatment difference between liraglutide 0.6 mg + metformin and placebo + metfomine was calculated. If the upper limit of the 95% CI was below 0%, it was concluded that the given dose of liraglutide in combination with metformin was better than the comparator therapy.</non_inferiority_desc>
            <p_value>0.9887</p_value>
            <method>ANCOVA</method>
            <param_type>Estimated treatment difference, LS Mean</param_type>
            <param_value>-0.07</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.57</ci_lower_limit>
            <ci_upper_limit>0.43</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Change in prandial increments of plasma glucose from baseline to 104 weeks of treatment was analyzed using an analysis of covariance (ANCOVA) model with treatment, country and previous anti-diabetic treatment as fixed effects and baseline value as covariate.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>A two-sided 95% CI for the treatment difference between liraglutide 0.6 mg + metformin and glimepirde + metfomine was calculated. If the upper limit of the 95% CI was below 0%, it was concluded that the given dose of liraglutide in combination with metformin was better than the comparator therapy.</non_inferiority_desc>
            <p_value>0.9998</p_value>
            <method>ANCOVA</method>
            <param_type>Estimated treatment difference, LS Mean</param_type>
            <param_value>0.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.38</ci_lower_limit>
            <ci_upper_limit>0.42</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Mean Post Prandial Plasma Glucose Based on Self-measured 7-point Plasma Glucose Profiles at Week 26</title>
        <description>Change in mean post prandial plasma glucose from baseline (Week 0) to 26 weeks (end of randomisation). The 7 time points for self-measurements were: before each meal (breakfast, lunch and dinner), at 90 min after start of each meal (breakfast, lunch and dinner) and at bedtime. Mean post prandial plasma glucose were calculated as the sum of the post pradial plasma glucose values divided by three.</description>
        <time_frame>week 0, week 26</time_frame>
        <population>Intention to treat (ITT) analysis set using LOCF (Last Observation Carried Forward) is all randomised subjects who had been exposed to at least one dose of the study products.</population>
        <group_list>
          <group group_id="O1">
            <title>Lira 0.6 + Met</title>
            <description>Liraglutide 0.6 mg/day + glimepiride placebo + metformin 1.5-2.0 g/day, weeks 0-26 (double-blinded period) and open-label liraglutide 0.6 mg/day + metformin 1.5-2.0 g/day in the extension period (weeks 26-104)</description>
          </group>
          <group group_id="O2">
            <title>Lira 1.2 + Met</title>
            <description>Liraglutide 1.2 mg/day + glimepiride placebo + metformin 1.5-2.0 g/day, weeks 0-26 (double-blinded period) and open-label liraglutide 1.2 mg/day + metformin 1.5-2.0 g/day in the extension period (weeks 26-104)</description>
          </group>
          <group group_id="O3">
            <title>Lira 1.8 + Met</title>
            <description>Liraglutide 1.8 mg/day + glimepiride placebo + metformin 1.5-2.0 g/day, weeks 0-26 (double-blinded period) and open-label liraglutide 1.8 mg/day + metformin 1.5-2.0 g/day in the extension period (weeks 26-104)</description>
          </group>
          <group group_id="O4">
            <title>Met Mono</title>
            <description>Metformin 1.5-2.0 g/day + liraglutide placebo + glimepiride placebo, weeks 0-26 (double-blinded period) and open-label metformin 1.5-2.0 g/day in the extension period (weeks 26-104)</description>
          </group>
          <group group_id="O5">
            <title>Met + Glim</title>
            <description>Glimepiride 4 mg/day + metformin 1.5-2.0 g/day + liraglutide placebo, weeks 0-26 (double-blinded period) and open-label glimepiride 4 mg/day + metformin 1.5-2.0 g/day in the extension period (weeks 26-104)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Mean Post Prandial Plasma Glucose Based on Self-measured 7-point Plasma Glucose Profiles at Week 26</title>
          <description>Change in mean post prandial plasma glucose from baseline (Week 0) to 26 weeks (end of randomisation). The 7 time points for self-measurements were: before each meal (breakfast, lunch and dinner), at 90 min after start of each meal (breakfast, lunch and dinner) and at bedtime. Mean post prandial plasma glucose were calculated as the sum of the post pradial plasma glucose values divided by three.</description>
          <population>Intention to treat (ITT) analysis set using LOCF (Last Observation Carried Forward) is all randomised subjects who had been exposed to at least one dose of the study products.</population>
          <units>mmol/L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="214"/>
                <count group_id="O2" value="207"/>
                <count group_id="O3" value="205"/>
                <count group_id="O4" value="90"/>
                <count group_id="O5" value="214"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.68" spread="0.16"/>
                    <measurement group_id="O2" value="-2.33" spread="0.17"/>
                    <measurement group_id="O3" value="-2.57" spread="0.16"/>
                    <measurement group_id="O4" value="-0.62" spread="0.24"/>
                    <measurement group_id="O5" value="-2.46" spread="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Change in post prandial increments of plasma glucose from baseline to 26 weeks of treatment was analyzed using an analysis of covariance (ANCOVA) model with treatment, country and previous anti-diabetic treatment as fixed effects and baseline value as covariate.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>A two-sided 95% CI for the treatment difference between liraglutide 1.8 mg + metformin and placebo + metfomine was calculated. If the upper limit of the 95% CI was below 0%, it was concluded that the given dose of liraglutide in combination with metformin was better than the comparator therapy.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Estimated treatment difference, LS Mean</param_type>
            <param_value>-1.95</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-2.60</ci_lower_limit>
            <ci_upper_limit>-1.30</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Change in post prandial increments of plasma glucose from baseline to 26 weeks of treatment was analyzed using an analysis of covariance (ANCOVA) model with treatment, country and previous anti-diabetic treatment as fixed effects and baseline value as covariate.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>A two-sided 95% CI for the treatment difference between liraglutide 1.8 mg + metformin and glimepiride + metfomine was calculated. If the upper limit of the 95% CI was below 0%, it was concluded that the given dose of liraglutide in combination with metformin was better than the comparator therapy.</non_inferiority_desc>
            <p_value>0.9670</p_value>
            <method>ANCOVA</method>
            <param_type>Estimated treatment difference, LS Mean</param_type>
            <param_value>-0.11</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.62</ci_lower_limit>
            <ci_upper_limit>0.41</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Change in post prandial increments of plasma glucose from baseline to 26 weeks of treatment was analyzed using an analysis of covariance (ANCOVA) model with treatment, country and previous anti-diabetic treatment as fixed effects and baseline value as covariate.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>A two-sided 95% CI for the treatment difference between liraglutide 1.2 mg + metformin and placebo + metfomine was calculated. If the upper limit of the 95% CI was below 0%, it was concluded that the given dose of liraglutide in combination with metformin was better than the comparator therapy.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Estimated treatment difference, LS Mean</param_type>
            <param_value>-1.72</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-2.36</ci_lower_limit>
            <ci_upper_limit>-1.07</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Change in post prandial increments of plasma glucose from baseline to 26 weeks of treatment was analyzed using an analysis of covariance (ANCOVA) model with treatment, country and previous anti-diabetic treatment as fixed effects and baseline value as covariate.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>A two-sided 95% CI for the treatment difference between liraglutide 1.2 mg + metformin and glimepirde + metfomine was calculated. If the upper limit of the 95% CI was below 0%, it was concluded that the given dose of liraglutide in combination with metformin was better than the comparator therapy.</non_inferiority_desc>
            <p_value>0.9368</p_value>
            <method>ANCOVA</method>
            <param_type>Estimated treatment difference, LS Mean</param_type>
            <param_value>0.13</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.39</ci_lower_limit>
            <ci_upper_limit>0.64</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Change in post prandial increments of plasma glucose from baseline to 26 weeks of treatment was analyzed using an analysis of covariance (ANCOVA) model with treatment, country and previous anti-diabetic treatment as fixed effects and baseline value as covariate.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>A two-sided 95% CI for the treatment difference between liraglutide 0.6 mg + metformin and placebo + metfomine was calculated. If the upper limit of the 95% CI was below 0%, it was concluded that the given dose of liraglutide in combination with metformin was better than the comparator therapy.</non_inferiority_desc>
            <p_value>0.0003</p_value>
            <method>ANCOVA</method>
            <param_type>Estimated treatment difference, LS Mean</param_type>
            <param_value>-1.06</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.71</ci_lower_limit>
            <ci_upper_limit>-0.42</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Change in post prandial increments of plasma glucose from baseline to 26 weeks of treatment was analyzed using an analysis of covariance (ANCOVA) model with treatment, country and previous anti-diabetic treatment as fixed effects and baseline value as covariate.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>A two-sided 95% CI for the treatment difference between liraglutide 0.6 mg + metformin and glimepirde + metfomine was calculated. If the upper limit of the 95% CI was below 0%, it was concluded that the given dose of liraglutide in combination with metformin was better than the comparator therapy.</non_inferiority_desc>
            <p_value>0.0008</p_value>
            <method>ANCOVA</method>
            <param_type>Estimated treatment difference, LS Mean</param_type>
            <param_value>0.78</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.27</ci_lower_limit>
            <ci_upper_limit>1.29</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Mean Post Prandial Plasma Glucose Based on Self-measured 7-point Plasma Glucose Profiles at Week 104</title>
        <description>Change in mean post prandial plasma glucose from baseline (Week 0) to 104 weeks (end of treatment) The 7 time points for self-measurements were: before each meal (breakfast, lunch and dinner), at 90 min after start of each meal (breakfast, lunch and dinner) and at bedtime. Mean post prandial plasma glucose were calculated as the sum of the post pradial plasma glucose values divided by three.</description>
        <time_frame>week 0, week 104</time_frame>
        <population>Intention to treat (ITT) analysis set using LOCF (Last Observation Carried Forward) is all randomised subjects who had been exposed to at least one dose of the study products.</population>
        <group_list>
          <group group_id="O1">
            <title>Lira 0.6 + Met</title>
            <description>Liraglutide 0.6 mg/day + glimepiride placebo + metformin 1.5-2.0 g/day, weeks 0-26 (double-blinded period) and open-label liraglutide 0.6 mg/day + metformin 1.5-2.0 g/day in the extension period (weeks 26-104)</description>
          </group>
          <group group_id="O2">
            <title>Lira 1.2 + Met</title>
            <description>Liraglutide 1.2 mg/day + glimepiride placebo + metformin 1.5-2.0 g/day, weeks 0-26 (double-blinded period) and open-label liraglutide 1.2 mg/day + metformin 1.5-2.0 g/day in the extension period (weeks 26-104)</description>
          </group>
          <group group_id="O3">
            <title>Lira 1.8 + Met</title>
            <description>Liraglutide 1.8 mg/day + glimepiride placebo + metformin 1.5-2.0 g/day, weeks 0-26 (double-blinded period) and open-label liraglutide 1.8 mg/day + metformin 1.5-2.0 g/day in the extension period (weeks 26-104)</description>
          </group>
          <group group_id="O4">
            <title>Met Mono</title>
            <description>Metformin 1.5-2.0 g/day + liraglutide placebo + glimepiride placebo, weeks 0-26 (double-blinded period) and open-label metformin 1.5-2.0 g/day in the extension period (weeks 26-104)</description>
          </group>
          <group group_id="O5">
            <title>Met + Glim</title>
            <description>Glimepiride 4 mg/day + metformin 1.5-2.0 g/day + liraglutide placebo, weeks 0-26 (double-blinded period) and open-label glimepiride 4 mg/day + metformin 1.5-2.0 g/day in the extension period (weeks 26-104)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Mean Post Prandial Plasma Glucose Based on Self-measured 7-point Plasma Glucose Profiles at Week 104</title>
          <description>Change in mean post prandial plasma glucose from baseline (Week 0) to 104 weeks (end of treatment) The 7 time points for self-measurements were: before each meal (breakfast, lunch and dinner), at 90 min after start of each meal (breakfast, lunch and dinner) and at bedtime. Mean post prandial plasma glucose were calculated as the sum of the post pradial plasma glucose values divided by three.</description>
          <population>Intention to treat (ITT) analysis set using LOCF (Last Observation Carried Forward) is all randomised subjects who had been exposed to at least one dose of the study products.</population>
          <units>mmol/L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="218"/>
                <count group_id="O2" value="208"/>
                <count group_id="O3" value="206"/>
                <count group_id="O4" value="90"/>
                <count group_id="O5" value="216"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.59" spread="0.18"/>
                    <measurement group_id="O2" value="-2.22" spread="0.18"/>
                    <measurement group_id="O3" value="-2.10" spread="0.18"/>
                    <measurement group_id="O4" value="-0.43" spread="0.26"/>
                    <measurement group_id="O5" value="-1.80" spread="0.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Change in post prandial increments of plasma glucose from baseline to 104 weeks of treatment was analyzed using an analysis of covariance (ANCOVA) model with treatment, country and previous anti-diabetic treatment as fixed effects and baseline value as covariate.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>A two-sided 95% CI for the treatment difference between liraglutide 1.8 mg + metformin and placebo + metfomine was calculated. If the upper limit of the 95% CI was below 0%, it was concluded that the given dose of liraglutide in combination with metformin was better than the comparator therapy.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Estimated treatment difference, LS Mean</param_type>
            <param_value>-1.66</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-2.37</ci_lower_limit>
            <ci_upper_limit>-0.96</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Change in post prandial increments of plasma glucose from baseline to 104 weeks of treatment was analyzed using an analysis of covariance (ANCOVA) model with treatment, country and previous anti-diabetic treatment as fixed effects and baseline value as covariate.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>A two-sided 95% CI for the treatment difference between liraglutide 1.8 mg + metformin and glimepiride + metfomine was calculated. If the upper limit of the 95% CI was below 0%, it was concluded that the given dose of liraglutide in combination with metformin was better than the comparator therapy.</non_inferiority_desc>
            <p_value>0.5048</p_value>
            <method>ANCOVA</method>
            <param_type>Estimated treatment difference, LS Mean</param_type>
            <param_value>-0.30</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.86</ci_lower_limit>
            <ci_upper_limit>0.26</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Change in post prandial increments of plasma glucose from baseline to 104 weeks of treatment was analyzed using an analysis of covariance (ANCOVA) model with treatment, country and previous anti-diabetic treatment as fixed effects and baseline value as covariate.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>A two-sided 95% CI for the treatment difference between liraglutide 1.2 mg + metformin and placebo + metfomine was calculated. If the upper limit of the 95% CI was below 0%, it was concluded that the given dose of liraglutide in combination with metformin was better than the comparator therapy.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Estimated treatment difference, LS Mean</param_type>
            <param_value>-1.79</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-2.49</ci_lower_limit>
            <ci_upper_limit>-1.08</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Change in post prandial increments of plasma glucose from baseline to 104 weeks of treatment was analyzed using an analysis of covariance (ANCOVA) model with treatment, country and previous anti-diabetic treatment as fixed effects and baseline value as covariate.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>A two-sided 95% CI for the treatment difference between liraglutide 1.2 mg + metformin and glimepirde + metfomine was calculated. If the upper limit of the 95% CI was below 0%, it was concluded that the given dose of liraglutide in combination with metformin was better than the comparator therapy.</non_inferiority_desc>
            <p_value>0.2005</p_value>
            <method>ANCOVA</method>
            <param_type>Estimated treatment difference, LS Mean</param_type>
            <param_value>-0.42</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.98</ci_lower_limit>
            <ci_upper_limit>0.14</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Change in post prandial increments of plasma glucose from baseline to 104 weeks of treatment was analyzed using an analysis of covariance (ANCOVA) model with treatment, country and previous anti-diabetic treatment as fixed effects and baseline value as covariate.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>A two-sided 95% CI for the treatment difference between liraglutide 0.6 mg + metformin and placebo + metfomine was calculated. If the upper limit of the 95% CI was below 0%, it was concluded that the given dose of liraglutide in combination with metformin was better than the comparator therapy.</non_inferiority_desc>
            <p_value>0.0003</p_value>
            <method>ANCOVA</method>
            <param_type>Estimated treatment difference, LS Mean</param_type>
            <param_value>-1.16</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.86</ci_lower_limit>
            <ci_upper_limit>-0.46</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Change in post prandial increments of plasma glucose from baseline to 104 weeks of treatment was analyzed using an analysis of covariance (ANCOVA) model with treatment, country and previous anti-diabetic treatment as fixed effects and baseline value as covariate.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>A two-sided 95% CI for the treatment difference between liraglutide 0.6 mg + metformin and glimepirde + metfomine was calculated. If the upper limit of the 95% CI was below 0%, it was concluded that the given dose of liraglutide in combination with metformin was better than the comparator therapy.</non_inferiority_desc>
            <p_value>0.7871</p_value>
            <method>ANCOVA</method>
            <param_type>Estimated treatment difference, LS Mean</param_type>
            <param_value>0.21</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.35</ci_lower_limit>
            <ci_upper_limit>0.76</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Beta-cell Function at Week 26</title>
        <description>Change in beta cell function from baseline (week 0) to 16 weeks (end of treatment). Beta-cell function was derived from fasting plasma glucose (FPG) and fasting insulin concentrations using the homeostasic model assessment (HOMA) method which uses the assumption that normal-weight normal subjects aged under 35 years have a 100% beta-cell function (HOMA-B).
Beta-cell function: HOMA-B (%) = 20∙fasting insulin[uU/mL] divided by (FPG mmol/L]-3.5).</description>
        <time_frame>week 0, week 26</time_frame>
        <population>Intention to treat (ITT) analysis set using LOCF (Last Observation Carried Forward) is all randomised subjects who had been exposed to at least one dose of the study products.</population>
        <group_list>
          <group group_id="O1">
            <title>Lira 0.6 + Met</title>
            <description>Liraglutide 0.6 mg/day + glimepiride placebo + metformin 1.5-2.0 g/day, weeks 0-26 (double-blinded period) and open-label liraglutide 0.6 mg/day + metformin 1.5-2.0 g/day in the extension period (weeks 26-104)</description>
          </group>
          <group group_id="O2">
            <title>Lira 1.2 + Met</title>
            <description>Liraglutide 1.2 mg/day + glimepiride placebo + metformin 1.5-2.0 g/day, weeks 0-26 (double-blinded period) and open-label liraglutide 1.2 mg/day + metformin 1.5-2.0 g/day in the extension period (weeks 26-104)</description>
          </group>
          <group group_id="O3">
            <title>Lira 1.8 + Met</title>
            <description>Liraglutide 1.8 mg/day + glimepiride placebo + metformin 1.5-2.0 g/day, weeks 0-26 (double-blinded period) and open-label liraglutide 1.8 mg/day + metformin 1.5-2.0 g/day in the extension period (weeks 26-104)</description>
          </group>
          <group group_id="O4">
            <title>Met Mono</title>
            <description>Metformin 1.5-2.0 g/day + liraglutide placebo + glimepiride placebo, weeks 0-26 (double-blinded period) and open-label metformin 1.5-2.0 g/day in the extension period (weeks 26-104)</description>
          </group>
          <group group_id="O5">
            <title>Met + Glim</title>
            <description>Glimepiride 4 mg/day + metformin 1.5-2.0 g/day + liraglutide placebo, weeks 0-26 (double-blinded period) and open-label glimepiride 4 mg/day + metformin 1.5-2.0 g/day in the extension period (weeks 26-104)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Beta-cell Function at Week 26</title>
          <description>Change in beta cell function from baseline (week 0) to 16 weeks (end of treatment). Beta-cell function was derived from fasting plasma glucose (FPG) and fasting insulin concentrations using the homeostasic model assessment (HOMA) method which uses the assumption that normal-weight normal subjects aged under 35 years have a 100% beta-cell function (HOMA-B).
Beta-cell function: HOMA-B (%) = 20∙fasting insulin[uU/mL] divided by (FPG mmol/L]-3.5).</description>
          <population>Intention to treat (ITT) analysis set using LOCF (Last Observation Carried Forward) is all randomised subjects who had been exposed to at least one dose of the study products.</population>
          <units>percentage point (%point)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="229"/>
                <count group_id="O2" value="224"/>
                <count group_id="O3" value="224"/>
                <count group_id="O4" value="109"/>
                <count group_id="O5" value="226"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.45" spread="5.19"/>
                    <measurement group_id="O2" value="20.33" spread="5.34"/>
                    <measurement group_id="O3" value="26.12" spread="5.20"/>
                    <measurement group_id="O4" value="-1.63" spread="7.19"/>
                    <measurement group_id="O5" value="24.68" spread="5.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Change in HOMA-B from baseline to 26 weeks of treatment was analyzed using an analysis of covariance (ANCOVA) model with treatment, country and previous anti-diabetic treatment as fixed effects and baseline value as covariate.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>A two-sided 95% CI for the treatment difference between liraglutide 1.8 mg + metformin and placebo + metfomine was calculated. If the upper limit of the 95% CI was below 0%, it was concluded that the given dose of liraglutide in combination with metformin was better than the comparator therapy.</non_inferiority_desc>
            <p_value>0.0031</p_value>
            <method>ANCOVA</method>
            <param_type>Estimated treatment difference, LS Mean</param_type>
            <param_value>27.75</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>7.83</ci_lower_limit>
            <ci_upper_limit>47.67</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Change in HOMA-B from baseline to 26 weeks of treatment was analyzed using an analysis of covariance (ANCOVA) model with treatment, country and previous anti-diabetic treatment as fixed effects and baseline value as covariate.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>A two-sided 95% CI for the treatment difference between liraglutide 1.8 mg + metformin and glimepiride + metfomine was calculated. If the upper limit of the 95% CI was below 0%, it was concluded that the given dose of liraglutide in combination with metformin was better than the comparator therapy.</non_inferiority_desc>
            <p_value>0.9987</p_value>
            <method>ANCOVA</method>
            <param_type>Estimated treatment difference, LS Mean</param_type>
            <param_value>1.44</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-15.03</ci_lower_limit>
            <ci_upper_limit>17.90</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Change in HOMA-B from baseline to 26 weeks of treatment was analyzed using an analysis of covariance (ANCOVA) model with treatment, country and previous anti-diabetic treatment as fixed effects and baseline value as covariate.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>A two-sided 95% CI for the treatment difference between liraglutide 1.2 mg + metformin and placebo + metfomine was calculated. If the upper limit of the 95% CI was below 0%, it was concluded that the given dose of liraglutide in combination with metformin was better than the comparator therapy.</non_inferiority_desc>
            <p_value>0.0263</p_value>
            <method>ANCOVA</method>
            <param_type>Estimated treatment difference, LS Mean</param_type>
            <param_value>21.96</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>2.04</ci_lower_limit>
            <ci_upper_limit>41.87</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Change in HOMA-B from baseline to 26 weeks of treatment was analyzed using an analysis of covariance (ANCOVA) model with treatment, country and previous anti-diabetic treatment as fixed effects and baseline value as covariate.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>A two-sided 95% CI for the treatment difference between liraglutide 1.2 mg + metformin and glimepirde + metfomine was calculated. If the upper limit of the 95% CI was below 0%, it was concluded that the given dose of liraglutide in combination with metformin was better than the comparator therapy.</non_inferiority_desc>
            <p_value>0.9227</p_value>
            <method>ANCOVA</method>
            <param_type>Estimated treatment difference, LS Mean</param_type>
            <param_value>-4.36</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-20.94</ci_lower_limit>
            <ci_upper_limit>12.22</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Change in HOMA-B from baseline to 26 weeks of treatment was analyzed using an analysis of covariance (ANCOVA) model with treatment, country and previous anti-diabetic treatment as fixed effects and baseline value as covariate.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>A two-sided 95% CI for the treatment difference between liraglutide 0.6 mg + metformin and placebo + metfomine was calculated. If the upper limit of the 95% CI was below 0%, it was concluded that the given dose of liraglutide in combination with metformin was better than the comparator therapy.</non_inferiority_desc>
            <p_value>0.0253</p_value>
            <method>ANCOVA</method>
            <param_type>Estimated treatment difference, LS Mean</param_type>
            <param_value>22.08</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>2.15</ci_lower_limit>
            <ci_upper_limit>42.01</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Change in HOMA-B from baseline to 26 weeks of treatment was analyzed using an analysis of covariance (ANCOVA) model with treatment, country and previous anti-diabetic treatment as fixed effects and baseline value as covariate.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>A two-sided 95% CI for the treatment difference between liraglutide 0.6 mg + metformin and glimepirde + metfomine was calculated. If the upper limit of the 95% CI was below 0%, it was concluded that the given dose of liraglutide in combination with metformin was better than the comparator therapy.</non_inferiority_desc>
            <p_value>0.9293</p_value>
            <method>ANCOVA</method>
            <param_type>Estimated treatment difference, LS Mean</param_type>
            <param_value>-4.23</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-20.78</ci_lower_limit>
            <ci_upper_limit>12.31</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Beta-cell Function at Week 104</title>
        <description>Change in beta cell function from baseline (week 0) to 16 weeks (end of treatment). Beta-cell function was derived from fasting plasma glucose (FPG) and fasting insulin concentrations using the homeostasic model assessment (HOMA) method which uses the assumption that normal-weight normal subjects aged under 35 years have a 100% beta-cell function (HOMA-B).
Beta-cell function: HOMA-B (%) = 20∙fasting insulin[uU/mL] divided by (FPG mmol/L]-3.5).</description>
        <time_frame>week 0, week 104</time_frame>
        <population>Intention to treat (ITT) analysis set using LOCF (Last Observation Carried Forward) is all randomised subjects who had been exposed to at least one dose of the study products.</population>
        <group_list>
          <group group_id="O1">
            <title>Lira 0.6 + Met</title>
            <description>Liraglutide 0.6 mg/day + glimepiride placebo + metformin 1.5-2.0 g/day, weeks 0-26 (double-blinded period) and open-label liraglutide 0.6 mg/day + metformin 1.5-2.0 g/day in the extension period (weeks 26-104)</description>
          </group>
          <group group_id="O2">
            <title>Lira 1.2 + Met</title>
            <description>Liraglutide 1.2 mg/day + glimepiride placebo + metformin 1.5-2.0 g/day, weeks 0-26 (double-blinded period) and open-label liraglutide 1.2 mg/day + metformin 1.5-2.0 g/day in the extension period (weeks 26-104)</description>
          </group>
          <group group_id="O3">
            <title>Lira 1.8 + Met</title>
            <description>Liraglutide 1.8 mg/day + glimepiride placebo + metformin 1.5-2.0 g/day, weeks 0-26 (double-blinded period) and open-label liraglutide 1.8 mg/day + metformin 1.5-2.0 g/day in the extension period (weeks 26-104)</description>
          </group>
          <group group_id="O4">
            <title>Met Mono</title>
            <description>Metformin 1.5-2.0 g/day + liraglutide placebo + glimepiride placebo, weeks 0-26 (double-blinded period) and open-label metformin 1.5-2.0 g/day in the extension period (weeks 26-104)</description>
          </group>
          <group group_id="O5">
            <title>Met + Glim</title>
            <description>Glimepiride 4 mg/day + metformin 1.5-2.0 g/day + liraglutide placebo, weeks 0-26 (double-blinded period) and open-label glimepiride 4 mg/day + metformin 1.5-2.0 g/day in the extension period (weeks 26-104)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Beta-cell Function at Week 104</title>
          <description>Change in beta cell function from baseline (week 0) to 16 weeks (end of treatment). Beta-cell function was derived from fasting plasma glucose (FPG) and fasting insulin concentrations using the homeostasic model assessment (HOMA) method which uses the assumption that normal-weight normal subjects aged under 35 years have a 100% beta-cell function (HOMA-B).
Beta-cell function: HOMA-B (%) = 20∙fasting insulin[uU/mL] divided by (FPG mmol/L]-3.5).</description>
          <population>Intention to treat (ITT) analysis set using LOCF (Last Observation Carried Forward) is all randomised subjects who had been exposed to at least one dose of the study products.</population>
          <units>percentage point (%point)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="230"/>
                <count group_id="O2" value="224"/>
                <count group_id="O3" value="224"/>
                <count group_id="O4" value="110"/>
                <count group_id="O5" value="226"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.48" spread="24.93"/>
                    <measurement group_id="O2" value="27.30" spread="25.70"/>
                    <measurement group_id="O3" value="17.81" spread="25.03"/>
                    <measurement group_id="O4" value="-7.89" spread="34.47"/>
                    <measurement group_id="O5" value="11.25" spread="25.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Change in HOMA-B from baseline to 104 weeks of treatment was analyzed using an analysis of covariance (ANCOVA) model with treatment, country and previous anti-diabetic treatment as fixed effects and baseline value as covariate.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>A two-sided 95% CI for the treatment difference between liraglutide 1.8 mg + metformin and placebo + metfomine was calculated. If the upper limit of the 95% CI was below 0%, it was concluded that the given dose of liraglutide in combination with metformin was better than the comparator therapy.</non_inferiority_desc>
            <p_value>0.8821</p_value>
            <method>ANCOVA</method>
            <param_type>Estimated treatment difference, LS Mean</param_type>
            <param_value>25.71</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-69.84</ci_lower_limit>
            <ci_upper_limit>121.26</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Change in HOMA-B from baseline to 104 weeks of treatment was analyzed using an analysis of covariance (ANCOVA) model with treatment, country and previous anti-diabetic treatment as fixed effects and baseline value as covariate.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>A two-sided 95% CI for the treatment difference between liraglutide 1.8 mg + metformin and glimepiride + metfomine was calculated. If the upper limit of the 95% CI was below 0%, it was concluded that the given dose of liraglutide in combination with metformin was better than the comparator therapy.</non_inferiority_desc>
            <p_value>0.9989</p_value>
            <method>ANCOVA</method>
            <param_type>Estimated treatment difference, LS Mean</param_type>
            <param_value>6.56</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-72.66</ci_lower_limit>
            <ci_upper_limit>85.79</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Change in HOMA-B from baseline to 104 weeks of treatment was analyzed using an analysis of covariance (ANCOVA) model with treatment, country and previous anti-diabetic treatment as fixed effects and baseline value as covariate.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>A two-sided 95% CI for the treatment difference between liraglutide 1.2 mg + metformin and placebo + metfomine was calculated. If the upper limit of the 95% CI was below 0%, it was concluded that the given dose of liraglutide in combination with metformin was better than the comparator therapy.</non_inferiority_desc>
            <p_value>0.7292</p_value>
            <method>ANCOVA</method>
            <param_type>Estimated treatment difference, LS Mean</param_type>
            <param_value>35.20</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-60.33</ci_lower_limit>
            <ci_upper_limit>130.72</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Change in HOMA-B from baseline to 104 weeks of treatment was analyzed using an analysis of covariance (ANCOVA) model with treatment, country and previous anti-diabetic treatment as fixed effects and baseline value as covariate.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>A two-sided 95% CI for the treatment difference between liraglutide 1.2 mg + metformin and glimepirde + metfomine was calculated. If the upper limit of the 95% CI was below 0%, it was concluded that the given dose of liraglutide in combination with metformin was better than the comparator therapy.</non_inferiority_desc>
            <p_value>0.9689</p_value>
            <method>ANCOVA</method>
            <param_type>Estimated treatment difference, LS Mean</param_type>
            <param_value>16.05</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-63.69</ci_lower_limit>
            <ci_upper_limit>95.79</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Change in HOMA-B from baseline to 104 weeks of treatment was analyzed using an analysis of covariance (ANCOVA) model with treatment, country and previous anti-diabetic treatment as fixed effects and baseline value as covariate.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>A two-sided 95% CI for the treatment difference between liraglutide 0.6 mg + metformin and placebo + metfomine was calculated. If the upper limit of the 95% CI was below 0%, it was concluded that the given dose of liraglutide in combination with metformin was better than the comparator therapy.</non_inferiority_desc>
            <p_value>0.1818</p_value>
            <method>ANCOVA</method>
            <param_type>Estimated treatment difference, LS Mean</param_type>
            <param_value>72.38</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-23.15</ci_lower_limit>
            <ci_upper_limit>167.90</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Change in HOMA-B from baseline to 104 weeks of treatment was analyzed using an analysis of covariance (ANCOVA) model with treatment, country and previous anti-diabetic treatment as fixed effects and baseline value as covariate.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>A two-sided 95% CI for the treatment difference between liraglutide 0.6 mg + metformin and glimepirde + metfomine was calculated. If the upper limit of the 95% CI was below 0%, it was concluded that the given dose of liraglutide in combination with metformin was better than the comparator therapy.</non_inferiority_desc>
            <p_value>0.2978</p_value>
            <method>ANCOVA</method>
            <param_type>Estimated treatment difference, LS Mean</param_type>
            <param_value>53.23</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-26.30</ci_lower_limit>
            <ci_upper_limit>132.76</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hypoglycaemic Episodes at Week 26</title>
        <description>Total number of hypoglycaemic episodes occuring after baseline (week 0) until week 26 (end of randomisation). Hypoglycaemic episodes were defined as major, minor, or symptoms only. Major if the subject was unable to treat her/himself. Minor if subject was able to treat her/himself and plasma glucose was below 3.1 mmol/L. Symptoms only if subject was able to treat her/himself and with no plasma glucose measurement or plasma glucose higher than or equal to 3.1 mmol/L.</description>
        <time_frame>weeks 0-26</time_frame>
        <population>Safety analysis set is all randomised subjects who were exposed to at least one dose of study product.</population>
        <group_list>
          <group group_id="O1">
            <title>Lira 0.6 + Met</title>
            <description>Liraglutide 0.6 mg/day + glimepiride placebo + metformin 1.5-2.0 g/day, weeks 0-26 (double-blinded period) and open-label liraglutide 0.6 mg/day + metformin 1.5-2.0 g/day in the extension period (weeks 26-104)</description>
          </group>
          <group group_id="O2">
            <title>Lira 1.2 + Met</title>
            <description>Liraglutide 1.2 mg/day + glimepiride placebo + metformin 1.5-2.0 g/day, weeks 0-26 (double-blinded period) and open-label liraglutide 1.2 mg/day + metformin 1.5-2.0 g/day in the extension period (weeks 26-104)</description>
          </group>
          <group group_id="O3">
            <title>Lira 1.8 + Met</title>
            <description>Liraglutide 1.8 mg/day + glimepiride placebo + metformin 1.5-2.0 g/day, weeks 0-26 (double-blinded period) and open-label liraglutide 1.8 mg/day + metformin 1.5-2.0 g/day in the extension period (weeks 26-104)</description>
          </group>
          <group group_id="O4">
            <title>Met Mono</title>
            <description>Metformin 1.5-2.0 g/day + liraglutide placebo + glimepiride placebo, weeks 0-26 (double-blinded period) and open-label metformin 1.5-2.0 g/day in the extension period (weeks 26-104)</description>
          </group>
          <group group_id="O5">
            <title>Met + Glim</title>
            <description>Glimepiride 4 mg/day + metformin 1.5-2.0 g/day + liraglutide placebo, weeks 0-26 (double-blinded period) and open-label glimepiride 4 mg/day + metformin 1.5-2.0 g/day in the extension period (weeks 26-104)</description>
          </group>
        </group_list>
        <measure>
          <title>Hypoglycaemic Episodes at Week 26</title>
          <description>Total number of hypoglycaemic episodes occuring after baseline (week 0) until week 26 (end of randomisation). Hypoglycaemic episodes were defined as major, minor, or symptoms only. Major if the subject was unable to treat her/himself. Minor if subject was able to treat her/himself and plasma glucose was below 3.1 mmol/L. Symptoms only if subject was able to treat her/himself and with no plasma glucose measurement or plasma glucose higher than or equal to 3.1 mmol/L.</description>
          <population>Safety analysis set is all randomised subjects who were exposed to at least one dose of study product.</population>
          <units>episodes</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="242"/>
                <count group_id="O2" value="240"/>
                <count group_id="O3" value="242"/>
                <count group_id="O4" value="121"/>
                <count group_id="O5" value="242"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Major</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Minor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="136"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Symptoms only</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="22"/>
                    <measurement group_id="O4" value="10"/>
                    <measurement group_id="O5" value="175"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hypoglycaemic Episodes at Week 104</title>
        <description>Total number of hypoglycaemic episodes occuring after baseline (week 0) until 104 weeks (end of treatment). Hypoglycaemic episodes were defined as major, minor, or symptoms only. Major if the subject was unable to treat her/himself. Minor if subject was able to treat her/himself and plasma glucose was below 3.1 mmol/L. Symptoms only if subject was able to treat her/himself and with no plasma glucose measurement or plasma glucose higher than or equal to 3.1 mmol/L.</description>
        <time_frame>weeks 0-104</time_frame>
        <population>Safety analysis set is all randomised subjects who were exposed to at least one dose of study product.</population>
        <group_list>
          <group group_id="O1">
            <title>Lira 0.6 + Met</title>
            <description>Liraglutide 0.6 mg/day + glimepiride placebo + metformin 1.5-2.0 g/day, weeks 0-26 (double-blinded period) and open-label liraglutide 0.6 mg/day + metformin 1.5-2.0 g/day in the extension period (weeks 26-104)</description>
          </group>
          <group group_id="O2">
            <title>Lira 1.2 + Met</title>
            <description>Liraglutide 1.2 mg/day + glimepiride placebo + metformin 1.5-2.0 g/day, weeks 0-26 (double-blinded period) and open-label liraglutide 1.2 mg/day + metformin 1.5-2.0 g/day in the extension period (weeks 26-104)</description>
          </group>
          <group group_id="O3">
            <title>Lira 1.8 + Met</title>
            <description>Liraglutide 1.8 mg/day + glimepiride placebo + metformin 1.5-2.0 g/day, weeks 0-26 (double-blinded period) and open-label liraglutide 1.8 mg/day + metformin 1.5-2.0 g/day in the extension period (weeks 26-104)</description>
          </group>
          <group group_id="O4">
            <title>Met Mono</title>
            <description>Metformin 1.5-2.0 g/day + liraglutide placebo + glimepiride placebo, weeks 0-26 (double-blinded period) and open-label metformin 1.5-2.0 g/day in the extension period (weeks 26-104)</description>
          </group>
          <group group_id="O5">
            <title>Met + Glim</title>
            <description>Glimepiride 4 mg/day + metformin 1.5-2.0 g/day + liraglutide placebo, weeks 0-26 (double-blinded period) and open-label glimepiride 4 mg/day + metformin 1.5-2.0 g/day in the extension period (weeks 26-104)</description>
          </group>
        </group_list>
        <measure>
          <title>Hypoglycaemic Episodes at Week 104</title>
          <description>Total number of hypoglycaemic episodes occuring after baseline (week 0) until 104 weeks (end of treatment). Hypoglycaemic episodes were defined as major, minor, or symptoms only. Major if the subject was unable to treat her/himself. Minor if subject was able to treat her/himself and plasma glucose was below 3.1 mmol/L. Symptoms only if subject was able to treat her/himself and with no plasma glucose measurement or plasma glucose higher than or equal to 3.1 mmol/L.</description>
          <population>Safety analysis set is all randomised subjects who were exposed to at least one dose of study product.</population>
          <units>episodes</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="242"/>
                <count group_id="O2" value="240"/>
                <count group_id="O3" value="242"/>
                <count group_id="O4" value="121"/>
                <count group_id="O5" value="242"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>All</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                    <measurement group_id="O2" value="51"/>
                    <measurement group_id="O3" value="49"/>
                    <measurement group_id="O4" value="18"/>
                    <measurement group_id="O5" value="524"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Major</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Minor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="26"/>
                    <measurement group_id="O3" value="22"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="284"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Symptoms only</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="27"/>
                    <measurement group_id="O4" value="12"/>
                    <measurement group_id="O5" value="240"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected over 24 months of treatment</time_frame>
      <desc>The safety analysis set is all randomised subjects who were exposed to at least one dose of study product.</desc>
      <group_list>
        <group group_id="E1">
          <title>Lira 0.6 + Met</title>
          <description>Liraglutide 0.6 mg/day + glimepiride placebo + metformin 1.5-2.0 g/day, weeks 0-26 (double-blinded period) and open-label liraglutide 0.6 mg/day + metformin 1.5-2.0 g/day in the extension period (weeks 26-104)</description>
        </group>
        <group group_id="E2">
          <title>Lira 1.2 + Met</title>
          <description>Liraglutide 1.2 mg/day + glimepiride placebo + metformin 1.5-2.0 g/day, weeks 0-26 (double-blinded period) and open-label liraglutide 1.2 mg/day + metformin 1.5-2.0 g/day in the extension period (weeks 26-104)</description>
        </group>
        <group group_id="E3">
          <title>Lira 1.8 + Met</title>
          <description>Liraglutide 1.8 mg/day + glimepiride placebo + metformin 1.5-2.0 g/day, weeks 0-26 (double-blinded period) and open-label liraglutide 1.8 mg/day + metformin 1.5-2.0 g/day in the extension period (weeks 26-104)</description>
        </group>
        <group group_id="E4">
          <title>Met Mono</title>
          <description>Metformin 1.5-2.0 g/day + liraglutide placebo + glimepiride placebo, weeks 0-26 (double-blinded period) and open-label metformin 1.5-2.0 g/day in the extension period (weeks 26-104)</description>
        </group>
        <group group_id="E5">
          <title>Met + Glim</title>
          <description>Glimepiride 4 mg/day + metformin 1.5-2.0 g/day + liraglutide placebo, weeks 0-26 (double-blinded period) and open-label glimepiride 4 mg/day + metformin 1.5-2.0 g/day in the extension period (weeks 26-104)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (11.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="242"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="240"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="242"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="121"/>
                <counts group_id="E5" subjects_affected="24" subjects_at_risk="242"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="240"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Congestive cardiomyopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Coronary artery occlusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Right ventricular failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Tachycardia paroxysmal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="121"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Vestibular disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="242"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Goitre</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Autoimmune thyroiditis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Uveitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="121"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Femoral hernia, obstructive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Hiatus hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Mallory-Weiss syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic cirrhosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Abscess sweat gland</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Infected skin ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="121"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Tuberculosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Wound sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="121"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="121"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Brain contusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Joint injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Sympathetic nerve injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Wound</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood calcitonin increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Electrocardiogram abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="121"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Heart rate increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="121"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="121"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="240"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Intervertebral disc disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Muscle disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Osteolysis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Spinal column stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Tendon disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Colon adenoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Hepatic neoplasm malignant</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Lung carcinoma cell type unspecified recurrent</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Malignant lymphoma unclassifiable high grade</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Rectal cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Renal cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Thyroid cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Thyroid neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Cerebral hypoperfusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="121"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Diabetic neuropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Haemorrhage intracranial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Calculus ureteric</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="242"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Menorrhagia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Testicular pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Obstructive airways disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Sleep apnoea syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Snoring</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Penile ulceration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="121"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Arterial stenosis limb</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="121"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Circulatory collapse</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (11.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="132" subjects_at_risk="242"/>
                <counts group_id="E2" subjects_affected="144" subjects_at_risk="240"/>
                <counts group_id="E3" subjects_affected="158" subjects_at_risk="242"/>
                <counts group_id="E4" subjects_affected="44" subjects_at_risk="121"/>
                <counts group_id="E5" subjects_affected="128" subjects_at_risk="242"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="33" subjects_affected="30" subjects_at_risk="242"/>
                <counts group_id="E2" events="50" subjects_affected="42" subjects_at_risk="240"/>
                <counts group_id="E3" events="70" subjects_affected="52" subjects_at_risk="242"/>
                <counts group_id="E4" events="6" subjects_affected="5" subjects_at_risk="121"/>
                <counts group_id="E5" events="14" subjects_affected="10" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="40" subjects_affected="31" subjects_at_risk="242"/>
                <counts group_id="E2" events="43" subjects_affected="27" subjects_at_risk="240"/>
                <counts group_id="E3" events="50" subjects_affected="40" subjects_at_risk="242"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="121"/>
                <counts group_id="E5" events="20" subjects_affected="14" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="21" subjects_affected="19" subjects_at_risk="242"/>
                <counts group_id="E2" events="22" subjects_affected="18" subjects_at_risk="240"/>
                <counts group_id="E3" events="26" subjects_affected="24" subjects_at_risk="242"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="13" subjects_affected="12" subjects_at_risk="242"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="240"/>
                <counts group_id="E3" events="27" subjects_affected="22" subjects_at_risk="242"/>
                <counts group_id="E4" events="4" subjects_affected="1" subjects_at_risk="121"/>
                <counts group_id="E5" events="11" subjects_affected="7" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="242"/>
                <counts group_id="E2" events="11" subjects_affected="8" subjects_at_risk="240"/>
                <counts group_id="E3" events="13" subjects_affected="13" subjects_at_risk="242"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="121"/>
                <counts group_id="E5" events="6" subjects_affected="4" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="242"/>
                <counts group_id="E2" events="14" subjects_affected="13" subjects_at_risk="240"/>
                <counts group_id="E3" events="8" subjects_affected="7" subjects_at_risk="242"/>
                <counts group_id="E4" events="8" subjects_affected="6" subjects_at_risk="121"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="242"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="69" subjects_affected="43" subjects_at_risk="242"/>
                <counts group_id="E2" events="70" subjects_affected="36" subjects_at_risk="240"/>
                <counts group_id="E3" events="43" subjects_affected="36" subjects_at_risk="242"/>
                <counts group_id="E4" events="21" subjects_affected="12" subjects_at_risk="121"/>
                <counts group_id="E5" events="80" subjects_affected="49" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="17" subjects_affected="14" subjects_at_risk="242"/>
                <counts group_id="E2" events="18" subjects_affected="15" subjects_at_risk="240"/>
                <counts group_id="E3" events="27" subjects_affected="17" subjects_at_risk="242"/>
                <counts group_id="E4" events="6" subjects_affected="5" subjects_at_risk="121"/>
                <counts group_id="E5" events="27" subjects_affected="18" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="16" subjects_affected="11" subjects_at_risk="242"/>
                <counts group_id="E2" events="19" subjects_affected="14" subjects_at_risk="240"/>
                <counts group_id="E3" events="19" subjects_affected="15" subjects_at_risk="242"/>
                <counts group_id="E4" events="6" subjects_affected="4" subjects_at_risk="121"/>
                <counts group_id="E5" events="19" subjects_affected="12" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="242"/>
                <counts group_id="E2" events="16" subjects_affected="13" subjects_at_risk="240"/>
                <counts group_id="E3" events="13" subjects_affected="12" subjects_at_risk="242"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="121"/>
                <counts group_id="E5" events="20" subjects_affected="15" subjects_at_risk="242"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="242"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="240"/>
                <counts group_id="E3" events="17" subjects_affected="15" subjects_at_risk="242"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="121"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="242"/>
                <counts group_id="E2" events="15" subjects_affected="14" subjects_at_risk="240"/>
                <counts group_id="E3" events="10" subjects_affected="10" subjects_at_risk="242"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="242"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="21" subjects_affected="16" subjects_at_risk="242"/>
                <counts group_id="E2" events="17" subjects_affected="15" subjects_at_risk="240"/>
                <counts group_id="E3" events="20" subjects_affected="17" subjects_at_risk="242"/>
                <counts group_id="E4" events="6" subjects_affected="5" subjects_at_risk="121"/>
                <counts group_id="E5" events="23" subjects_affected="21" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="15" subjects_affected="14" subjects_at_risk="242"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="240"/>
                <counts group_id="E3" events="12" subjects_affected="9" subjects_at_risk="242"/>
                <counts group_id="E4" events="7" subjects_affected="5" subjects_at_risk="121"/>
                <counts group_id="E5" events="22" subjects_affected="19" subjects_at_risk="242"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="41" subjects_affected="26" subjects_at_risk="242"/>
                <counts group_id="E2" events="40" subjects_affected="34" subjects_at_risk="240"/>
                <counts group_id="E3" events="51" subjects_affected="35" subjects_at_risk="242"/>
                <counts group_id="E4" events="8" subjects_affected="8" subjects_at_risk="121"/>
                <counts group_id="E5" events="55" subjects_affected="32" subjects_at_risk="242"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="242"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="240"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="121"/>
                <counts group_id="E5" events="16" subjects_affected="13" subjects_at_risk="242"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="242"/>
                <counts group_id="E2" events="15" subjects_affected="13" subjects_at_risk="240"/>
                <counts group_id="E3" events="11" subjects_affected="11" subjects_at_risk="242"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="121"/>
                <counts group_id="E5" events="12" subjects_affected="12" subjects_at_risk="242"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Novo Nordisk acknowledges the Investigator’s right to publish the entire results of the trial. Any such scientific paper, presentation, communication or other information concerning the investigation described in this protocol, must be submitted in writing to Novo Nordisk Trial Manager prior to submission for publication/presentation for comments. Comments will be given within four weeks from receipt of the manuscript.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Public Access to Clinical Trials</name_or_title>
      <organization>Novo Nordisk A/S</organization>
      <email>clinicaltrials@novonordisk.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

